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Peripheral vascular disease (PVD) affects more than 202 million people globally 
and about 20% of the population above 65 years of age in the United States alone. Type-2 
diabetes afflicts around 347 million people worldwide and leads to the death of 4.6 
million people. The rising prevalence of strong risk factors like smoking, hypertension, 
hypercholesterolemia, and obesity indicate that the affected population will continue to 
grow. Currently no long-term therapies exist in clinical practice for peripheral ischemia 
and non-healing chronic ulcers, both of which are common clinical consequences of PVD 
and type-2 diabetes. Current clinical treatments including exercise therapy, pharmaco-
therapy, and surgical intervention can provide only relatively short-term relief from 
progressive vascular disease. Some attractive therapeutic strategies are to use growth 
factors, cytokines, viral delivery of growth factor genes, or the implantation of stem cells 
to revascularize ischemic tissue and heal chronic wounds. While these emerging therapies 
have been successfully applied in healthy animal models, they have achieved only limited 
success in humans with long-term disease. Thus, the overall goal of this thesis is to 
understand the reasons behind the failure of the clinical trials using growth factor therapy 
and to engineer therapeutics to circumvent the problems.  
 
 ix 
We observed a dramatic reduction in the protein levels of growth factor co-
receptors, including syndecan-4, in the diabetic mouse model. We speculated that since 
co-receptors are critical for growth factor signaling cascade, this reduction in expression 
might lead to inefficient growth factor signaling. Our hypothesis was confirmed in the 
diseased ob/ob mice where we observed significant resistance to angiogenesis via growth 
factor therapy. Co-delivery of syndecan-4 along with fibroblast growth factor-2 (FGF-2) 
in an optimized liposomal formulation (syndesome) drastically improved the body’s 
responsiveness to FGF-2. Treatment with syndesomes also enhanced revascularization in 
ischemic hind limbs and increased wound healing in full thickness cutaneous wounds in 
the diseased mouse model. The studies performed and described here are the first 
attempt, to our knowledge, for an effective understanding of the mechanisms involved in 
metabolic disorder in humans due to long-term disease and to explore steps for 
overcoming the associated clinical problems.  
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1 
Chapter 1: Introduction 
 
1.1 MOTIVATION  
Type-2 diabetes and peripheral vascular disease (PVD) have become more 
prevalent worldwide in the last few decades with the increase in average life expectancy 
leading to an older, diseased population [1]. PVD affects more than 202 million people 
worldwide and about 8.5 million people over 40 years of age in United States alone [1-6]. 
Type-2 diabetes affects around 347 million people and kills about 4.6 million people 
worldwide [7, 8]. Peripheral ischemia and non-healing wounds have emerged as 
clinically interdependent complications in both PVD and type-2 diabetes afflicted 
population. Statisticians predict that this affected population will continue to rise unless 
the risk factors are modified [1]. Presently, no long-term therapies exist in clinical 
practice to remedy ischemia and chronic wounds. Clinical standards only provide short-
term relief from the symptoms [9]. An appealing therapeutic strategy is to deliver 
angiogenic factors to revive the diseased tissue to a relatively healthy state. This strategy 
has been highly successful in restoring perfusion in the ischemic tissues and healing 
wounds in healthy animal models. However, the delivery of growth factors [10, 11], 
cytokines [12], viral delivery of growth factor genes [13-16], and implantation of bone 
marrow cells [17] have achieved extremely limited success in clinical trials of diseased 
human patients [18, 19]. This thesis aims to understand why these growth factor based 
therapies have failed and seeks to create novel therapeutics to increase growth factor 
effectiveness in this context. 
 
 
2 
We hypothesized that the presence of co-morbid disease states inherently alters 
the ability of the body to respond to angiogenic therapies. To compare between the 
healthy and diseased state, we used a mouse model with diabetes and obesity called ob/ob 
(spontaneous mutation in the leptin gene leading to leptin deficiency) and wild type mice 
(C57BL/6J), which were healthy and age matched to the ob/ob mice. We examined 
alterations in the major components for the signaling pathways for FGF, VEGF, and 
PDGF. Both types of mice were fed with normal or high fat diet food to simulate the 
entire spectrum of diseased states i.e. from healthy mice on normal diet to obese mice on 
unhealthy high fat diet. In skeletal muscle of wild type healthy mice, a high fat diet 
increased protein levels of growth factor receptors and co-receptors including syndecan-
1, syndecan-4, and PDGFR-α. These increases did not occur in ob/ob mice on a high fat 
diet. We found similar trends in myocardial tissue as well. To assess the responsiveness 
to growth factor therapy, we subcutaneously implanted alginate hydrogels encapsulating 
FGF-2, VEGF-A, or PDGF-CC. We found a drastic difference in therapeutic 
angiogenesis between the healthy and diseased groups. With the aim of increasing growth 
factor effectiveness in the context of disease, we examined whether co-delivery of FGF-2 
with syndecan-4, which was depleted in the diseased tissue, could overcome the growth 
factor resistance in these mice. This syndesome (syndecan-4 protein embedded in a 
liposomal membrane) treatment enhanced the formation of new blood vessels in ob/ob 
mice by 6 fold in comparison to FGF-2 delivered alone. We tested the syndesomal 
therapy in clinically relevant mouse models of ischemia and wound healing. The 
syndesome with FGF-2 treatment significantly improved outcomes in a hind limb 
ischemia model in ob/ob mice compared to FGF-2 alone. We also demonstrated 
enhanced wound healing at day 14 with the syndesome and FGF-2 treatment. Our studies 
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support that diseased states cause a profound shift in growth factor signaling pathways 
and that co-receptor-based therapies have the potential to overcome growth factor 
resistance by restoring the tissue to a healthier phenotype. 
 
1.2 DISSERTATION ROADMAP 
The motivation behind this dissertation and the comprehensive summary of the 
thesis research are introduced in Chapter 1. A brief background and prior work are 
discussed in Chapter 2. Chapter 3 describes the extensive molecular study, specifically 
gene and protein expression experiments targeting various growth factors and their 
receptors and co-receptors. It includes the in vivo subcutaneous implantation study to 
assess the responsiveness to growth factors in healthy and diseased state. Chapter 4 
discusses the syndesome therapy that was developed to overcome the disease-induced 
growth factor resistance. Chapters 5 and 6 represent the attempts to understand the 
clinically interdependent conditions of ischemia and chronic ulcers, and assess the 
effectiveness of the syndesomal therapy. Chapter 5 describes the experiments for efficacy 
of the syndesome treatment for peripheral ischemia in a clinically relevant diseased ob/ob 
mouse model. Chapter 6 describes the syndesomal therapeutics for enhancing wound 
healing in ob/ob mice. Finally, Chapter 7 concludes the dissertation and presents future 
research directions. 
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Chapter 2: Background 
 
2.1 PERIPHERAL VASCULAR DISEASE 
Peripheral vascular disease (PVD) affects about 202 million people worldwide [1] 
and 8.5 million people in USA, which is 20% of the general population over 65 years of 
age[2, 20]. PVD is in fact the third most prevalent cause for mortality after stroke and 
coronary artery disease [1]. Lower and middle-income countries and low-income groups 
in high-income countries have an elevated risk of PVD and associated cardiovascular 
complications [1, 21]. PVD poses a significant burden on not only physical health but 
also mental health, work productivity, and greater usage of healthcare resources [22]. The 
increase in prevalence of strong risk factors for PVD, including smoking, diabetes, 
hypercholesterolemia, and obesity indicate that the affected population will continue to 
grow [1, 23]. A major sequela of PVD is the development of ischemia (reduction in blood 
flow) in the extremities. Severe PVD has serious clinical consequences for patients 
including the formation of chronic ulcers, pain from intermittent claudication and 
ultimately, increased risk for limb amputation [4, 24]. Although 50% of the patients are 
asymptomatic, their prognoses steadily worsens with time [4]. The 5-year mortality rate 
among patients with symptomatic PAD is about 20% [25]. Of those patients who develop 
critical limb ischemia, one out of four require amputation and 25% die due to other 
cardiovascular complications [26].  
PVD manifests with other co-morbid cardiovascular problems like coronary 
artery disease, stroke, and other thromboembolic events. Therefore, managing PVD 
becomes a multifaceted problem. Abnormal muscle bioenergetics, ischemia due to 
 
 
5 
atherosclerosis, and endothelial dysfunction all contribute towards PVD. Interestingly, 
Fiotti et al showed that although PVD elevates haptoglobin, α1AT, TNF-α, IL-1β, and 
IL-6 soluble receptors, there were no significant increases in inflammatory cytokines 
[27]. These findings and others have warranted the search for novel biomarkers to detect 
PVD in its initial phases. D-dimer (two cross-linked D fragments of the fibrin protein 
formed after degradation of blood clot by fibrinolysis) has been demonstrated to be a 
marker for short-term outcomes [28] while circulating microRNAs have been shown to 
be correlative to disease progression [29]. Scientists have also developed a plethora of in 
vivo imaging techniques to diagnose PVD in early stages [30]. While these methods have 
shown promise, as of now, none of them have translated to the clinic. 
For many years the most prevalent clinical treatment for PVD was composed 
either of pharmacological interventions aimed at treating the progress of vascular 
disease/co-morbidities or surgical revascularization through bypass grafting and 
endarterectomy [31]. More recently, there has been a rapid growth in the number of 
endovascular treatments such as angioplasty, stenting, and catheter-based atherectomy for 
PVD, although the overall benefit of these treatments versus surgery remains unclear 
[32]. For a significant portion of the clinical population, these methods are insufficient to 
restore blood flow over the long-term course of their disease [33]. Unfortunately, while 
each of these treatment modalities provides some benefit for some patients in the short-
term, for many patients the disease is poorly managed by these therapies. A major 
limitation of these treatments is their reduced clinical durability due to restenosis and 
continuation of the atherosclerotic disease process.  
An appealing and potentially revolutionary strategy for treating ischemia is the 
stimulation of angiogenesis within the ischemic tissue, harnessing the body’s own 
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regenerative capacity to restore blood flow [34]. Previous studies have explored this 
strategy using exogenously-applied growth factors [10, 35, 36], viral vectors to express 
growth factor/angiogenic transcription factor genes [10, 15, 16, 37-43], or the 
implantation or mobilization of progenitors cells [38]. Unfortunately, while many of 
these strategies have shown promise in animal studies or small-scale clinical trials, none 
have found significant improvement in large randomized clinical trials [44]. Therefore, 
clinically effective angiogenic therapies remain elusive. 
 
2.2 DIABETES MELLITUS 
Type-2 diabetes, also known as diabetes mellitus, has been called the “epidemic 
of our generation” and it is estimated by the World Health Organization that 347 million 
people suffer from diabetes worldwide [45, 46]. In USA, there are around 29.1 million 
people with diabetes out of which 27.8% are still undiagnosed [47].  It is generally more 
common in men than women and most prevalent in people over the age of 65 years [48, 
49]. The most troubling fact is that 1.7 million new cases of diabetes have been reported 
in a single year of 2012, which is 8 out of every 1000 people in USA [50]. Diabetes 
contributes for an immense financial burden on USA, accounting for a total of $245 
billion every year, which includes $176 billion of direct medical costs and $69 billion of 
indirect costs [47].  
Diabetic patients have abnormal pancreatic function which leads to glucose 
insensitivity and deficiency of insulin hormone. A host of other problems accompany 
diabetes including but not limited to heart disease, stroke, hypertension, 
hypercholesterolemia, neuropathy, nephropathy, chronic kidney disease, peripheral 
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vascular disease, non-alcoholic fatty liver, periodontal disease, erectile dysfunction, loss 
of hearing, depression, and pregnancy complications [47]. Neuropathy and microvascular 
angiopathy are common complications of diabetes and contribute to a 12-25% lifetime 
risk of developing diabetic ulcers [51]. Diabetic foot ulcers, specifically, are responsible 
for 25-50% of the total cost of diabetes treatment [52] and are the most common cause 
for limb amputations in the United States [53]. Diabetic ulcers are a complex clinical 
problem requiring a multifaceted treatment plan with standard therapeutic components 
including debridement of necrotic tissue, offloading, infection control, surgical 
revascularization, and limb elevation/compression [18, 19]. Unfortunately, these 
treatments routinely fail, leaving patients with chronic ulcers with an enhanced risk for 
limb amputation.  
 
2.3 ANGIOGENESIS 
Angiogenesis is an intricate physiological process requiring the complex 
coordination of endothelial cells, vascular smooth muscle cells, pericytes, and 
macrophages under the control of environmental cues from the extracellular matrix and a 
host of growth factors/cytokines [54]. Among these, members of the FGF family bind to 
cell surface heparan sulfate proteoglycans, interactions that are essential to stabilize the 
formation of active FGF-FGF receptor complexes [55]. Consequently, cell surface 
heparan sulfate proteoglycans, such as the syndecans, serve as essential co-receptors in 
this pathway. Vascular endothelial growth factor (VEGF) has also been recognized as a 
potent stimulator of endothelial proliferation/migration and plays an integral role in 
angiogenesis in vivo through interactions with its two primary receptors Flt-1 (VEGFR-1) 
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and KDR (VEGFR-2) [56]. Neuropilin-1 is a major co-receptor for VEGF acting to 
facilitate signaling with both Flt-1 and KDR [57]. In addition, syndecan-2 can bind 
VEGF and is essential for VEGF-mediated angiogenesis [58]. Platelet-derived growth 
factor-BB (PDGF-BB) is involved in pericyte recruitment around capillaries during 
angiogenesis and is consequently involved in blood vessel stabilization during 
angiogenesis and arteriogenesis [59]. The PDGF-β receptor has the high affinity for 
PDGF-BB, and this interaction has been linked to the control of cell migration and 
proliferation [60]. Both neuropilin-1 and the syndecans have been linked to regulation of 
PDGF activity [61-64]. In addition, PDGF-CC interacts with the PDGF-α and β 
receptors, inducing angiogenesis [65] and revascularization of ischemic tissues [66].  
Given the intense study of the process of angiogenesis and the evidence for the 
potent induction of angiogenesis by growth factors in experimental models, we 
hypothesize that the reason for this therapeutic failure may lie in disease-mediated 
alterations in target tissue signaling. In animal models, ischemia is typically induced in a 
healthy animal by surgically ligating an artery either in the peripheral muscle or coronary 
arteries. Consequently, ischemia develops acutely in an animal that is often otherwise 
healthy. In human clinical use, the patient has developed ischemia most often through a 
long-term disease process. Thus, by the time patients have developed clinically-
recognizable symptoms, they have had the disease for an extended period of time and the 
compensatory mechanisms of the human body may have been overwhelmed 
considerably. These mechanisms include, in all likelihood, the induction of the very 
angiogenic factors that we are attempting to use as therapeutic inducers of blood vessel 
growth. Accordingly, the presence of long-term ischemic disease in humans likely 
implies the presence of mechanisms to defeat growth factor therapy without modification. 
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Here, we explored this hypothesis by examining how the expression of signaling 
components of FGF-2, VEGF-A, and PDGF pathways change with diseased state caused 
by a high fat diet in the ob/ob mouse model. Our group has also recently shown that 
delivery of liposomally embedded co-receptors are effective in enhancing growth factor-
induced signaling and trafficking in the cell as well as revascularization in healthy rats 
[67]. To examine if this strategy could overcome disease-induced growth factor 
resistance, we developed an alginate-based hydrogel system for the local delivery of 
syndecan-4 in combination with FGF-2.  
 
2.4 SYNDECAN-4 
A complex extracellular matrix (ECM) also called connective tissue, surrounds 
most mammalian cells. The ECM is composed of a variety of biomolecules including 
structural proteins (collagen, elastin), specialized proteins (fibrillin, fibronectin, and 
laminin), and proteoglycans. Proteoglycans are ubiquitous proteins with one or more 
GAG (glycosaminoglycan) chains attached to a core protein through a typical core 
protein region ending in a xylose residue linked to the hydroxyl group of a serine residue. 
They typically have a 90-95% carbohydrate content due to the GAG chains. 
Proteoglycans are different from glycoproteins, which are proteins with one or more 
glycans covalently attached to a polypeptide chain usually via N or O linkages with 2-
30% carbohydrate content [68]. Proteoglycans are heavily glycosylated, generally with 
sulfate or uronic acid groups, which imparts a net negative charge to the protein. 
Proteoglycans are of four different kinds according to the glycosylations - chondroitin 
sulfate, dermatan sulfate, keratin sulfate, and heparan sulfate [68]. 
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 Heparan sulfate proteoglycans (HSPGs) are a specialized group of proteoglycans, 
which as the name suggests, contain heparan sulfate glycosylations. Among the four 
kinds of proteoglycans, HSPGs are perhaps the most versatile and hence most studied. 
They can be found as transmembrane or as extracellular matrix proteins. HSPGs have 
been implicated in diverse roles at cellular, tissue, and organismal levels. The HSPGs on 
the cell surface like glypicans and syndecans coordinate multiple cellular functions like 
binding to growth factors, receptors, ECM, and intracellular signaling [69, 70].  Overall, 
HSPGs contribute in cell proliferation, migration, adhesion, recognition, differentiation, 
matrix assembly, survival, hemostasis, defense mechanism, inflammation, and 
angiogenesis [71, 72].  Among the HSPGs, the syndecan family consists of four single-
pass transmembrane proteins with a long extracellular domain with heparan sulfate and 
chondroitin sulfate chains and a relatively short intracellular domain. They interact with 
FGF, VEGF, TGF-β, PDGF, ECM proteins, and cytosolic proteins like FRS2, Ras, Akt, 
MAPK, Elk3, Erg1, and cFos [73, 74]. Syndecans generally dimerize or polymerize into 
complexes to exert its effects on other transmembrane protein. They regulate various 
physiological functions like wound repair [75-77], inflammation [78, 79], angiogenesis 
[80], migration [81, 82], body weight, and synaptic plasticity [83].  
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Figure 2.1 Schematic diagram showing the interactions on the cell membrane among 
the growth factors (FGF-2, VEGF-A, and PDGF-CC), the receptors (FGFR-
1, PDGFR-α/β, and VEGFR-2), and the co-receptors (Syndecan-1, -2, -4, 
and Neuropilin-1). 
We are interested in syndecan-4 in this study among the syndecan family.  
Syndecan-4 is ubiquitously found in the body in almost all cell types and exerts a crucial 
role in the microenvironment. It has only one isomer but can be converted into a soluble 
form by cleavage of the extracellular domain by proteases [84, 85]. These soluble forms 
have been shown to be a marker of acute myocardial infarction. Previous studies support 
a role for syndecan-4 in wound healing and have found that syndecan-4 gene expression 
promotes fibroblast migration and regulates integrin signaling and small GTPases during 
wound healing [77, 86]. Syndecan-4 also enhances keratinocyte migration [81] and is 
necessary for migration of fibroblasts in 3D gels [87]. In addition, syndecan-4 is induced 
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in the skin following wounding in both mice and neonatal humans [88]. Finally, mice 
with knockout of syndecan-4 gene have delayed wound healing and angiogenesis [75]. 
Syndecan-4 is one of the co-receptors for FGFR-1 that binds to FGF-2 (Figure 2.1). Our 
previous studies have shown that syndesomes improve the signaling response to FGF-2, 
proliferation, migration and the nuclear localization of FGF-2 in endothelial cells (Figure 
2.2) [67]. In addition, we found that syndesomes improved the angiogenic response to 
FGF-2 in diabetic mice in a subcutaneous implantation model [89].  
Figure 2.2 Schematic diagram showing formation of syndecan-4 loaded liposomes and 
treatment to endothelial cells. 
 
2.5 MOUSE MODELS 
We have used two different mouse models in this thesis:  C57BL/6J mouse (WT -
normal healthy mice) and B6.Cg-Lep ob/J (ob/ob - diseased diabetic mice). The WT mice 
are the most widely used strain in the scientific studies and the first to have its genome 
sequenced. They have a permissive genetic background that allows scientists to induce 
spontaneous mutations in their genome to create various models of disease. The ob/ob 
mice are a result of one such spontaneous mutation in the leptin gene that results in the 
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inactivation of the gene. C57BL/6J mice are used in a wide variety of research areas 
including cardiovascular biology, developmental biology, diabetes, obesity, genetics, 
immunology, neurobiology, and sensorineural research. Overall, C57BL/6 mice breed 
well, are long-lived, and have a low susceptibility to tumors. 
 
Figure 2.3 An ob/ob mouse model for diabetes and metabolic disease. A 10-week old 
male ob/ob mouse (left) that is fed for 10 weeks with a high fat diet (right) 
doubles its weight and becomes pre-diabetic with the symptoms of insulin 
resistance, hyperglycemia, and glucose insensitivity.  
The ob/ob mice exhibit obesity, hyperphagia, diabetes-like syndrome of 
hyperglycemia, glucose intolerance, elevated plasma insulin, subfertility, impaired wound 
healing, and an increase in hormone production from both pituitary and adrenal glands. 
They are also hypometabolic and hypothermic. The obesity is characterized by an 
increase in both the number and the size of adipocytes. Although hyperphagia contributes 
to the obesity, homozygotes gain excess weight, and deposit excess fat even when 
restricted to a diet sufficient for normal weight maintenance in lean mice. Since the ob/ob 
mice have a C57BL/6J background strain, they are perfect match for our experiments 
with healthy WT mice. 
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Chapter 3: Disease-induced Growth Factor Resistance 
3.1 INTRODUCTION 
Growth factor based therapy is an interesting therapeutic strategy for 
revascularization, wound healing, and other clinical conditions. While these techniques 
have shown remarkable results in normal healthy animals, they have failed to show 
significant differences when compared with a placebo or clinical standard of care in 
human diseased patients. We hypothesize that resistance exists not only for insulin [90] 
but also for growth factors including FGF-2, VEGF-A, and PDGF-CC isoforms. Previous 
studies have indirectly supported this hypothesis by demonstrating reduced wound 
healing in diabetic animals [91], a reduced capacity for ischemic pre-conditioning in 
reperfusion injury in ob/ob mice [92], and a defective response to angiogenic gene 
therapy in db/db mice that are deficient of the leptin receptor [93]. A previous study 
examined the broad set of gene expression following ischemia in WT and db/db mice 
using microarray analysis [94], which supported the occurrence of reduced 
vascularization in these mice and alterations in angiogenic gene regulatory networks. 
In this chapter we investigate the gene and protein expression levels of receptors 
and co-receptors of various growth factors in different phases of disease progression. We 
simulated the human disease and sequela with an ob/ob mouse model [95]. These mice 
are pre-diabetic, obese, and show many characteristics similar to patients with long-term 
metabolic disease. We postulated that there must be some dysregulation at the cellular 
level due to presence of long-term disease. To evaluate the degree of resistance to growth 
factor therapy in a diseased state, we used a subcutaneous implantation model in the 
ob/ob mouse.  
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3.2 MATERIALS AND METHODS 
3.2.1 Animal Model  
All animal studies were performed with the approval of the University of Texas at 
Austin’s Institutional Animal Care and Use Committee (IACUC) and in accordance with 
NIH guidelines “Guide for Care and Use of Laboratory Animals” for animal care. Wild 
type mice - C57BL/6J (Jackson Labs) and ob/ob mice - B6.Cg-Lepob/J (Jackson Labs) 
were used in these studies. The ob/ob mice are deficient of the hormone leptin that is 
normally produced by the fat cells, signaling the brain to stop the hunger signal. 
Therefore, these mice are chronically hyperphagic leading to obesity, subfertility, 
impaired wound healing and pre-diabetes like symptoms of insulin resistance, glucose 
intolerance, and elevated plasma insulin. The animals were fed normal chow diet 
(LabDiet - Prolab RMH 1800) or high fat diet (Research Diets - D12331). Thus, we had 4 
different groups henceforth referred as follows: WT-NCD (WT mice on normal chow 
diet), WT-HFD (WT mice on high fat diet), ob/ob-NCD (ob/ob mice on normal chow 
diet), and ob/ob-HFD (ob/ob mice on high fat diet). The mice were fed a particular diet 
for 10 weeks and then sacrificed to harvest the heart and quadriceps muscle for 
downstream processing, as described in section 3.2.6.  
3.2.2 Gene Expression Analyses  
Slices of the tissue were sectioned (10-20μm) with a Leica CM 1850 cryotome 
equipped with a steel knife. The tissue sections were dissolved in the RLT buffer 
(Qiagen) using a TissueLyzer with a stainless steel bead. RNA was isolated using the 
Qiagen RNeasy Midi kit and purity checked on an UV-Vis spectrophotometer (Nanodrop 
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2000c). Pure RNA was reverse transcribed into cDNA using the TaqMan Reverse 
Transcription reagents (Applied Biosystems). The cDNA was used with SYBR Green 
PCR master mix (Life Technologies) for real-time qPCR quantification using the Applied 
Biosystems ViiA™7 system. GAPDH was used as the reference gene. The cycling 
conditions used were 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds 
and 60°C for 60 seconds. Primers for the PCR reactions are listed below in Table 3.1. 
Table 3.1 Primers used for real time qPCR, adapted from [89]. 
 
3.2.3 Protein Expression Analyses  
The tissues were cryosectioned and the slices lysed in a buffer containing the 
following: 20mM Tris at pH 8, 150mM NaCl, 1% Triton, 0.1% SDS, 2mM Sodium 
Orthovanadate, 2mM PMSF, 50mM NaF, and protease inhibitors (Roche). A Qiagen 
Tissuelyzer was used with stainless steel beads to facilitate tissue lysis. The lysates were 
 
Gene Forward Primer Reverse Primer 
FGFR-1 ACCAAGAAGAGCGACTTCCA AACCAGGAGAACCCCAGAGT 
VEGFR-2 TTTGGTTTTGGAAGGTTTGC AGGAGCAAGCTGCATCATTT 
PDGFR-α ACCACAATGGTGCTGTTGAA AATCTCTGGGGCAAAGGTCT 
PDGFR-β CCGGAACAAACACACCTTCT TATCCATGTAGCCACCGTCA 
Syndecan-1 AGCCTTCCTCCCTCATGTTT TCTAGCTGAGTGGCTGAGCA 
Syndecan-2 ACATCTCCCCTTGCTGTGAC TGAGGGGTTCTTTGGTCTTG 
Syndecan-4 CTGATCCTGCTGCTGGTGTA GGAGGAAGCTTCATGCGTAG 
Neuropilin-1 GGAGCTACTGGGCTGTGAAG CCTCCTGTGAGCTGGAAGTC 
Heparanase GGAGCAGGCAACTACCACTT ACAGGAGCAAACTCCGAGTG 
GAPDH AACTTTGGCATTGTGGAAGG GGATGCAGGGATGATGTTCT 
 
Abbreviations used were as follows: FGFR-1 = Fibroblast Growth Factor-1; VEGFR-2 = Vascular 
Endothelial Growth Factor; PDGFR-α = Platelet Derived Growth Factor Alpha; PDGFR-β = 
Platelet Derived Growth Factor Beta; GAPDH = Glyceraldehyde 3-Phosphate Dehydrogenase. 
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normalized to the amount of protein loaded into the wells by performing a Micro-BCA 
assay (Thermo-Scientific). The samples were then separated by gel electrophoresis 
(NuPAGE® Novex 10% Bis-Tris Midi Gel) and transferred onto a nitrocellulose 
membrane using the iBlot system (Life Technologies). The membranes were then 
blocked for 1h in 5% non-fat milk in PBS with 0.01% Tween-20 and exposed to primary 
antibodies (see Table 3.2 below for details) overnight at 4°C. The membranes were 
washed and incubated at room temperature for 2h at room temperature with a secondary 
antibody and were detected using a chemiluminescence substrate (Thermo Fisher 
Scientific). Imaging was performed using the FluorChem HD2 system (Protein Simple). 
Quantification of the blots was done by densitometric analysis using Metamorph. 
Table 3.2 Antibodies used in the studies, adapted from [89]. 
 
 
Protein/Label Antibody Type Company 
GAPDH Mouse monoclonal Primary Santa Cruz 
Syndecan-1 Mouse monoclonal Primary ABCAM 
Syndecan-2 Rabbit polyclonal Primary ABCAM 
Syndecan-4 Rabbit polyclonal Primary ABCAM 
Neuropilin-1 Rabbit monoclonal Primary ABCAM 
Heparanase Mouse monoclonal Primary Cell Sciences 
PDGFR-α Rabbit polyclonal Primary ABCAM 
pPDGFR-α Rabbit monoclonal Primary Cell Signaling 
PDGFR-β Rabbit monoclonal Primary Cell Signaling 
FGFR-1 Rabbit polyclonal Primary ABCAM 
PECAM Goat polyclonal Primary Santa Cruz 
VEGFR2/KDR Rat monoclonal Primary Santa Cruz 
AlexaFluor 594 Donkey polyclonal Secondary Life Tech 
HRP Donkey polyclonal Secondary Santa Cruz 
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3.2.4 Implant Preparation 
Equal volumes of 4% sodium alginate solution and 0.85% NaCl solution were 
mixed, and then growth factors were added to the solution. The mixture solution was then 
extruded through a syringe with an 18G needle attached via luer lock into 1.1% CaCl2 
solution and cross-linked for 1h at 4°C. One bead was implanted in each of the 
subcutaneous pockets created (as described in the section 3.2.5 below). 10μg of the 
growth factors were encapsulated in a 400μl mixture solution that formed 12 alginate 
beads.  
3.2.5 Subcutaneous Implantation Model 
Prior to this subcutaneous implantation surgery, the animals were fed for 15 
weeks on normal or high fat diet to replicate the long-term diseased state in humans. The 
aim of this study was to examine the resistance to therapeutic angiogenesis via exogenous 
addition of growth factors. There were two groups for the subcutaneous implantation 
surgeries - WT mice on normal chow diet and ob/ob mice on high fat diet - representing 
the two ends of the disease extent.  
The dorsal surface of the mouse was clipped, depilated, and prepared with a swab 
of Betadine followed by a swab of 70% ethanol and repeating the swabs three times 
consecutively. A skin incision was made on the back with a scissors and blunt dissections 
(using hemostats) were used to create four subcutaneous pockets, two on each side of the 
midline. An alginate bead containing growth factors or a control solution was implanted 
in the subcutaneous space. The wound was closed using resorbable sutures (Ethicon 5-0 
polydioxanone sutures). After 7 days, the animals were sacrificed. To perform en-face 
imaging of the gels, the full thickness skin of the entire dorsal surface was removed and 
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mounted on a dissection tray. The alginate gels were then imaged macroscopically and 
were flash frozen in liquid N2-cooled isopentane along with the surrounding skin tissue 
for subsequent analysis. 
3.2.6 Histological Analyses and Immunostaining 
Eight-micron thick sections were obtained from frozen tissues using the Leica 
CM 1850 Cryotome equipped with steel knife. For H&E staining, the sections were fixed 
in 10% formalin for 10 minutes, washed in 1X PBS for 5 minutes and then air dried at 
60°C for 1h. The standard H&E protocol [96] was then followed and imaged with an 
upright compound microscope. Briefly, after a wash in distilled water, the sections were 
stained in Harris Hematoxylin solution for 8 minutes. This was followed by a 5-minute 
wash in running tap water to get rid of excess hematoxylin. Then the slides were put in 
differentiation buffer for 30 seconds and quickly washed under running tap water for 1 
minute. This was followed by staining in Bluing reagent for 1 minute, a wash in running 
tap water for 5 minutes, a rinse in 95% alcohol, a counterstain in Eosin solution for 1 
minute, a dehydration step using 95% alcohol, and finally two changes of absolute 
alcohol, 5 minutes each. The stains were cleared in two changes of xylene, 5 minutes 
each, and mounted with xylene-based mounting medium and cover glasses. 
The slides with the sections on them were also stained by standard Movat’s 
Pentachrome staining procedure [97] to investigate the anatomical features. The slides 
were placed in a slide rack and mordanted with Bouin’s fluid for 1 hour at 50°C. Traces 
of Picric acid were removed by washing in running water for 2 minutes. They were then 
stained in 1% Alcian Blue for 20 minutes and washed in distilled water by dipping 5 
times in the bucket. Then the slides were placed in Alkaline alcohol for 10 minutes at 
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56°C. Slides were washed in running water for 2 minutes. Then they were stained in 
Orcein-Verheoff Hematoxylin solution for 15 minutes and washed in distilled water 
twice by dipping, and then running tap water rinses. This step is the crucial as it stains for 
collagen and elastin. This was followed by Woodstain Scarlet-Acid Fuchsin stain for 2.5 
minutes, 0.5% Acetic acid for 30 seconds, 5% Phosphotungstic acid for 7.5 minutes, 0.5 
Acetic acid for 30 seconds and ultimately, 3 ethanol washes of 1 minute each. The slides 
were then stained with Alcoholic Saffron for 8 minutes and 2 ethanol washes with three 
dips each. To clean the slides at the end, two 30-second dips in Xylene were used and 
then mounted with cover glass and Cytoseal™. 
For immunohistochemical staining, the sections were fixed in 4% 
paraformaldehyde for 5-10 minutes, blocked with 25% FBS for 45 minutes and then 
exposed to a 1:50 dilution of primary antibody (refer Table 3.2 for details) overnight at 
4°C. The following day, samples were washed three times with PBS and treated with a 
1:500 dilution of secondary antibody conjugated to a fluorescent marker (Table 3.2) for 
2h at room temperature. The slides were rinsed with PBS and cover glass mounted using 
DAPI containing anti-fade mounting medium (Vector Labs). Imaging was performed 
with the Zeiss Axiovert or Leica SP2 AOBS, and images were analyzed using Photoshop 
and Metamorph.  
3.2.7 Statistical Analysis 
All results were shown as mean + SEM. An ANOVA with Duncan post-hoc test 
was used to make comparisons between groups of continuous variables. When comparing 
between two groups only, Student’s t-test was used. A two tailed probability with p-
value, p < 0.05 was considered statistically significant. 
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3.3 RESULTS 
3.3.1 Gene Expression in Diseased Skeletal Muscle Tissue 
To better understand the potential mechanisms underlying growth factor 
resistance in pre-diabetic, hyperlipidemic ob/ob mice, we fed these mice with 10 weeks 
of a high fat or normal chow diet and examined gene expression in the heart and muscle 
tissue. We first examined the quadriceps muscle tissue for gene expression levels of 
receptors and co-receptors for the FGF-2, VEGF-A, and PDGF-CC pathways.  
At the mRNA expression level, we did not notice any significant changes within 
the WT-NCD and WT-HFD groups for all of the genes except heparanase. However, we 
found a 5- to 28-fold increase in ob/ob-HFD group for the gene expression of growth 
factor receptors/co-receptors including syndecan-1 (sdc-1), syndecan-4 (sdc-4), 
neuropilin-1 (nrp-1), FGFR-1, and VEGFR-2 (Figure 3.1). For WT-HFD group, we 
found a significant increase in heparanase, an enzyme that degrades heparan sulfate 
proteoglycans and mediates the release of angiogenic factor from the extracellular matrix 
[98]. This trend was absent in the ob/ob mice groups. An overall summary of the gene 
expression is shown in Table 3.3. 
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Table 3.3 Summary of Gene Expression Relative to WT Mice on a Normal Chow Diet 
(NCD), adapted from [89].  
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Figure 3.1 Gene expression in quadriceps muscle harvested from wild type (WT) and 
ob/ob mice after 10 weeks of normal chow diet (NCD) or high fat diet 
(HFD). Measurements were made using real time qPCR and are normalized 
to GAPDH expression and expressed relative to the mRNA levels of WT 
mice on NCD. n=10. Adapted from [89]. 
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3.3.2 Protein Expression in Diseased Skeletal Muscle Tissue 
We wanted to be certain about our findings and therefore, checked the protein 
expression levels of the receptors and co-receptors in the healthy and diseased tissues. 
Generally, it is expected that protein expression levels will be directly proportional to the 
gene expression levels in cells. Surprisingly, we observed a markedly different profile at 
the protein level compared to the gene expression levels in the muscle tissues.  
For the co-receptors sdc-1, sdc-2, and sdc-4, and receptor PDGFR-α there was an 
increase in protein levels in WT-HFD group compared with WT-NCD (Figure 3.2). 
Interestingly, this increase was absent in the ob/ob mice. On the contrary, there was a 
significant reduction in the protein expression for the nrp-1 in ob/ob mice in comparison 
to the WT mice. All the protein levels were normalized by the protein mass in the tissue. 
We performed a GAPDH blot and found that the portion of GAPDH per unit protein was 
increased in the high fat diet group of the WT mice, and reduced in the ob/ob mice on 
high fat diet, suggesting a change in the number of cells per mg of protein in the tissue. 
The levels of heparanase protein corresponded well to the results for mRNA levels in the 
tissues, with an increase for the WT-HFD group and significant decrease in heparanase in 
the ob/ob-HFD group. An overall summary of the protein expression is shown in Table 
3.4. 
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Table 3.4 Summary of Protein Expression Relative to WT Mice on a Normal Chow 
Diet, adapted from [89]. 
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Figure 3.2 Protein expression of growth factor receptors and co-receptors in skeletal 
muscle harvested from wild type (WT) and ob/ob mice fed with normal 
chow diet (NCD) or high fat diet (HFD) for 10 weeks. Measurements are 
performed using densitometric analysis and expressed relative to the protein 
expression of WT mice on NCD. n=10. Adapted from [89]. 
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Figure 3.3 Gene expression in heart tissue harvested from wild type (WT) and ob/ob 
mice after 10 weeks of normal chow diet (NCD) or high fat diet (HFD). 
Measurements were made using real time qPCR and are normalized to 
GAPDH expression and expressed relative to the mRNA levels of WT mice 
on NCD. n=10. Adapted from [89]. 
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3.3.3 Gene Expression in Diseased Myocardial Muscle Tissue 
To examine if different mouse tissues were affected in a differential manner, we 
also analyzed the gene expression of growth factor receptors and co-receptors in 
myocardial tissue. We found that there were increased mRNA expressions for the 
syndecans and VEGFR-2 in ob/ob mice (both HFD and NCD groups), almost similar to 
the skeletal muscle results (Figure 3.3).  For nrp-1, there was increased gene expression 
in the ob/ob groups and the WT-HFD group. The most striking result was a dramatic loss 
in gene expression for PDGFR-α (less than 3% of baseline WT levels) in the ob/ob-HFD 
group. We still have not figured out why this is happening but we speculate that it might 
be related to stem cell activity in the heart. A summary of these results can be found in 
Table 3.3.  
3.3.4  Protein Expression in Diseased Myocardial Muscle Tissue 
Similar to the results for skeletal muscle, we found a decrease in protein levels of 
receptors and co-receptors in contrast to gene expression levels, in the heart muscle. High 
fat diet induced an increase in the protein levels of sdc-1, -2, and -4 in WT mice, which 
was not observed in ob/ob mice (Figure 3.4). There was a similar trend for PDGFR-α 
with an over three-fold increase for WT-HFD group but a decrease in protein levels for 
the ob/ob-HFD group. Heparanase also increased in the WT-HFD but had WT baseline 
levels for both the groups of ob/ob mice. The overall summary of these results is shown 
in Table 3.4.  
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Figure 3.4 Protein expression of growth factor receptors and co-receptors in myocardial 
tissue harvested from wild type (WT) and ob/ob mice fed with normal chow 
diet (NCD) or high fat diet (HFD) for 10 weeks. Measurements are 
performed using densitometric analysis and expressed relative to the protein 
expression of WT mice on NCD. n=10. Adapted from [89]. 
 
Syndecan-1 Syndecan-2 Syndecan-4 Neuropilin-1
WT WF Ob Fat0
2
4
6
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
p < 0.05 
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0
1
2
3
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
p < 0.05 
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0.0
0.5
1.0
1.5
2.0
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0
1
2
3
4
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0.0
0.5
1.0
1.5
2.0
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0
2
4
6
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
p < 0.05 
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0
1
2
3
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
p < 0.05
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0.0
0.5
1.0
1.5
2.0
2.5
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
p < 0.05 
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0.0
0.5
1.0
1.5
2.0
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0.0
0.5
1.0
1.5
2.0
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
  WT      WT    Ob/Ob  Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0
2
4
6
8
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
p < 0.05 
  WT      WT   Ob/Ob  Ob/Ob
 NCD    HFD   NCD    HFD
Strain:
Diet: 
WT WF Ob Fat0
1
2
3
4
5
N
or
m
. P
ro
te
in
 E
xp
re
ss
io
n
  WT      WT    Ob/Ob Ob/Ob
 NCD    HFD    NCD    HFD
Strain:
Diet: 
FGFR-1 VEGFR-2 PDGFR-β Heparanase
GAPDH PDGFR-αp-PDGFR-α p-PDGFR-α/PDGFR-α
 
 
30 
3.3.5  Growth Factor Responsiveness in the Diabetic ob/ob Mouse Model 
To examine whether ob/ob mice had growth factor resistance compared with WT 
mice, we implanted alginate gels that contained control (PBS), FGF-2, VEGF-A, or 
PDGF-CC, subcutaneously in the mice. We had two mouse groups - WT mice on normal 
chow diet and ob/ob mice on high fat diet. After 7 days, we found that there was little 
response to the control gel, both macroscopically (Figure 3.5A) and on histological 
analysis (Figure 3.6A). In WT mice, gels containing FGF-2 demonstrated increased 
vascularity (Figure 3.5B) as well as a thicker surrounding layer of vascularized tissue 
(Figure 3.6A,B, and Figure 3.7). In these mice, gels containing VEGF-A or PDGF-CC 
also had increased vascularity and moderately increased formation of a vascularized 
cellular layer. In ob/ob mice, vascularity and vascularized layer thickness was markedly 
decreased in the FGF-2 or PDGF-CC treated mice compared with the WT mice with the 
same treatments (Figure 3.5B). The decrease in cellular layer thickness (Figure 3.6B) was 
statistically significant in the FGF-2 and PDGF-CC groups. We also performed H&E and 
Movat’s Pentachrome staining to the tissue micro-sections. The results showed that for 
both the mice, the surrounding layers were primarily cellular (Figure 3.6A, Figure 3.7). 
The cellular layer was confirmed to be composed of cells with high vascularity since they 
stained positively for CD31, also called PECAM-1, an endothelial cell marker (Figure 
3.8). Histochemical staining confirmed the lack of fibrotic tissue (Figure 3.6A, Figure 
3.7) and fluorescent immunostaining for CD45 (leukocyte common antigen) was negative 
for the surrounding tissue. Together these findings confirmed that WT mice had a more 
robust growth factor response compared with the ob/ob mice and supported the existence 
of growth factor resistance in this animal model. 
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Figure 3.5 In vivo mouse model to test growth factor resistance by subcutaneously 
implanting alginate gels containing PBS, FGF-2, VEGF-A, or PDGF-CC on 
the back of mice. The gels were harvested after 7 days and macroscopically 
imaged (A). Vascularity on the gel was determined for the macroscopic 
images using Metamorph (B). Panel A - size bar = 3mm. Mag. size bar = 
1mm. *Statistically different from WT group (p < 0.05). n=6. Adapted from 
[89].  
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Figure 3.6 Gels harvested along with the native skin, frozen, sectioned, and H&E 
stained (A). The thickness of the vascular layer was quantified by analyzing 
the H&E stained images using Metamorph (B). *Statistically different from 
WT group (p < 0.05). n=6. Adapted from [89]. 
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Figure 3.7 Movat’s Pentachrome staining of the sections of alginate gels with PBS, 
FGF-2, VEGF-A, or PDGF-CC. The gels were harvested after 7 days 
frozen, sectioned, and stained as shown here. Size bar = 1mm. Mag. size bar 
= 250μm. n=6. Adapted from [89]. 
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Figure 3.8 Sections immunostained with anti-PECAM1 antibody and imaged with an epifluorescence microscope. Size bar = 
250μm. *Statistically different from ob/ob group (p < 0.05). n=6. Adapted from [89]. 
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3.4 DISCUSSION 
Diabetes and metabolic syndrome are major contributors to cardiovascular risk 
and mortality. Both diabetes and obesity have been associated with a loss of 
microvascular density and reduced formation of collateralization in ischemic tissues [99, 
100]. Here, we show that the ob/ob mouse model has growth factor resistance in the 
context of therapeutic angiogenesis, to multiple growth factors including FGF-2, VEGF-
A, and PDGF-CC. The results of this study also reveal a previously unrecognized loss in 
co-receptor levels in ob/ob mice and have broad implications in both understanding the 
mechanisms of growth factor resistance and designing new effective angiogenic 
therapies. One of the key findings of this study is the potential pitfall of drawing 
conclusions of growth factor pathway status through the use of gene expression analysis, 
particularly for receptors and co-receptors. In both the heart and muscle samples we 
found a paradoxical increase in mRNA levels in contrast to the protein levels of the 
receptors/co-receptors. Some potential implications of these findings include either post-
transcriptional mechanisms of regulation for these proteins or increased 
degradation/shedding of these molecules resulting in removal of the protein from the cell 
surface. Syndecans, in particular, are known to be shed from the surface through the 
action of proteases [66].  In either case, it is clear from our studies that a proteomic rather 
than genomic approach to studying these pathways is required to capture the full 
complexity of the regulation of these processes due to diabetes and high fat diet.  
The regulation of the growth factor receptors and co-receptors had a remarkably 
similar regulation for all the signaling pathways studied. The archetypal pattern was an 
increase in protein expression in the WT mice on a high fat diet, with no change in the 
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ob/ob mice on a high fat diet. A possible explanation for these findings is that with an 
unhealthy high fat diet that likely causes the initial stages of endothelial dysfunction and 
vascular disease, the WT mice being analogous to healthy people, up-regulate their 
angiogenic pathways. The ob/ob mice that are compromised by their additional metabolic 
defects could not compensate by increasing their receptor levels. This finding is 
consistent with the finding of previous studies that show an increase in neuropilin-1 (nrp-
1) in WT mice following ischemia and no change in nrp-1 in db/db mice after induction 
of ischemia [94]. Thus, ob/ob mice have an altered compensation to disease that may in 
part recapitulate the long-term diseased state in human patients. In our studies, 
heparanase was found to increase with high fat diet in the WT mice. This finding is 
consistent with a previous study that demonstrated up-regulation of heparanase by fatty 
acids [101]. Our group has recently linked heparanase to restenosis and thrombosis 
following stenting [102, 103] and in the pathogenesis of atherosclerosis [104]. 
Heparanase is also linked to angiogenesis and is found to release angiogenic growth 
factors from sequestration in heparan sulfate proteoglycans [98]. Interestingly, elevated 
heparanase levels were not observed in ob/ob mice fed with high fat diet in our studies. 
This would suggest that the elevation of heparanase levels is critical for compensatory 
revascularization under the high fat diet in WT mice; however, this mechanism does not 
occur with the additional defects in the ob/ob mice.  
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3.5 CONCLUSIONS 
Angiogenic therapies have generated great interest both in animal studies and in 
clinical trials. However, despite these many promising animal studies, no therapies have 
shown clinically meaningful benefits in controlled clinical trials. Our findings here 
suggest that this may be due to the development of growth factor resistance in patients 
with long-term disease that is absent when using healthy animal models. In this work, we 
have identified multiple defects in growth factor signaling pathways that involve loss of 
receptors and co-receptors at the protein level. 
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Chapter 4: Syndesome Therapy Characterization and Overcoming the 
Disease-Induced Growth Factor Resistance in ob/ob mice 
4.1 INTRODUCTION 
Our laboratory recently showed that syndesomes with fibroblast growth factor-2 
(FGF-2) enhance migration, proliferation, and tube formation in human endothelial cells 
[67]. In vivo studies showed markedly improved neovascularization following femoral 
artery ligation in normal healthy rats treated with syndesomes (Figure 4.1). Ischemic 
limbs completely recovered in 7 days when treated with FGF-2 and syndesomes, 
compared with only partial recovery when treated with FGF-2 only. This trend continued 
beyond 16 days. The syndecans are a family of single-pass transmembrane proteins that 
can serve as co-receptors for FGF [105, 106]. Syndecans have sites for post-translational 
glycosylation with heparan sulfate chains that lend them this remarkable repertoire of 
physiological functions. 
Therefore, we hypothesize that a major contributing factor in the failure of 
therapeutic revascularization therapies is the presence of long-term disease, which 
fundamentally alters the biology of angiogenesis in patients with PVD that leads to 
“growth factor resistance.” We attribute this resistance to exhausted compensatory 
mechanisms in the diseased tissue. In this chapter, we demonstrate the optimization of the 
syndesome therapy. We use the therapy to reinstate the levels of syndecan-4 in the 
diseased tissue. We envision that by doing so, the diseased tissue will be revived to its 
native healthy phenotype and will respond to the growth factor treatment. 
 
 
 
39 
4.2 MATERIALS AND METHODS 
4.2.1 Protein Production 
A constitutive expression vector containing the full-length syndecan-4 gene 
(Genecopoeia) was transduced into HEK-293Ta cells (Genecopoeia) using the Lenti-Pac 
transduction kit (Genecopoeia). Two days post-transduction, cell lysis was performed 
with a buffer containing the following: 20mM Tris (pH 8.0), 150mM NaCl, 1% Triton X-
100, 0.1% SDS, 2mM sodium orthovanadate, 2mM PMSF, 50mM NaF, and protease 
inhibitors (Roche). The lysates were clarified by centrifugation for 15 minutes at 15,000 
× g, and the supernatant was collected. The pooled lysates were desalted and separated 
sequentially using ion exchange and affinity chromatography. The separations were 
performed with an AKTA FPLC (GE Healthcare) using a Q anion exchange column. The 
samples were then concentrated using a Centriprep (Millipore). SDS-PAGE and silver 
staining were used to analyze the purity of the final concentrated samples. 
4.2.2 Syndesome Fabrication 
Syndesomes are liposomal nanoparticles with the syndecan-4 transmembrane 
proteins embedded on the membrane. Standard lipid stock solutions were prepared at 
10mg/ml concentration in chloroform. The following lipids were used: 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE), cholesterol, and sphingomyelin (Avanti Polar Lipids) mixed in a ratio of 
40:20:20:20 by volume, respectively. The solution mixture was prepared in a round-
bottom flask, and the solvent was removed first using a rotatory evaporator (Heidolph 
Collegiate) for 1h and then under a stream of argon gas for 15 minutes. The lipid film 
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was then resuspended in a HEPES-buffered salt solution (10.0mM HEPES and 150mM 
NaCl in PBS, pH 7.4) by mixing, sonicating, and freeze-thawing to achieve a final 
solution of 13.2mM total lipid. The final lipid solution was then extruded through a 
400nm polycarbonate membrane (Avestin). A detergent, 1% n-octyl-β-D-
glucopyranoside (OG), was added to both the 13.2mM lipid and the 25μg/ml syndecan-4 
protein solutions. The concentration of the solution was reduced to 40% of the original in 
10% increments every 30 minutes through dilution with PBS. The detergent and free 
protein was removed by extensive dialysis in PBS at 4°C. Residual OG was removed by 
repeated BioBead treatments (SM-2; Bio-Rad). The resulting syndesome solution was 
stored at 4°C with gentle shaking to reduce aggregation. 
 
 
Figure 4.1 Extrusion apparatus used for fabricating liposomes. 
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Figure 4.2 Schematic diagram showing syndesomes that have syndecan-4 protein 
embedded on the membrane. 
4.2.3 Syndesome Characterization  
The size and dispersion of the syndesomes were characterized by dynamic light 
scattering (Malvern Zetasizer Nano ZS). The instrument was calibrated using 54 nm 
polystyrene particles. The syndesomes were diluted 1:1000 to fit the detection region of 
the instrument and then aliquoted into a polystyrene cuvette to run in the machine. The 
results were averaged over 50 size measurements. For TEM, the syndesomes were 
infused with cryo-protectant for at least one hour. The samples were mounted onto cryo 
pins and frozen rapidly under liquid N2. The cryo pins were stored in cryo vials in liquid 
N2 Dewar flask until they were sectioned. The 50-80 nm sections were imaged on the 
cryo TEM (FEI Technai Spirit Transmission Electron Microscope) 
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4.2.4 Implant Preparation  
Alginate hydrogels in the form of tiny spherical beads were used, similar to those 
used in the last study to probe growth factor resistance. Equal volumes of 4% sodium 
alginate (Sigma™) solution and 0.85% NaCl (Sigma™) solution were mixed and the 
syndesomes and/or growth factors were added to it. The solution was extruded through a 
syringe with an 18G needle into a 1.1% CaCl2 solution and cross-linked for 1 hour at 
4°C. For growth factor delivery, 10μg of the growth factors were encapsulated in 400μl 
solution to form 12 beads. For S4PL+FGF-2, 5μg of syndesomes and 10μg of FGF were 
added to 400μl of the solution to form 14 beads. 
4.2.5 Animal Model  
The ob/ob also called B6.Cg-Lepob/J (Jackson Labs) diseased mouse model was 
used for these studies. Since disease resistance was observed in this model, it made sense 
to test whether the co-delivery of growth factors with co-receptors might increase the 
potency of the growth factor activity. All animal studies were performed with the 
approval of the University of Texas at Austin’s Institutional Animal Care and Use 
Committee (IACUC) and in accordance with NIH guidelines “Guide for Care and Use of 
Laboratory Animals” for animal care. Wild type mice C57BL/6J (Jackson Labs) were 
used as control healthy animals. The WT mice were fed normal chow diet (LabDiet - 
Prolab RMH 1800) and ob/ob mice were fed the high fat diet (Research Diets - D12331). 
The animals were fed for 15 weeks to simulate healthy, and long-term diseased state in 
humans before performing the subcutaneous implantation surgery. 
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4.2.6 Subcutaneous Implantation  
The mice were fed for 15 weeks to simulate the normal and long-term diseased 
states in humans before examining the resistance to therapeutic angiogenesis via 
exogenous addition of growth factors. There were two groups for the subcutaneous 
implantation surgeries - WT mice on normal chow diet and ob/ob mice on high fat diet, 
representing two ends of the disease spectrum.  
The dorsal surface of the mouse was clipped, depilated, and prepared with a swab 
of Betadine followed by a swab of 70% ethanol and repeating the swabs three times 
consecutively. A skin incision was made on the back with a scissor and blunt dissections 
(using hemostats) were used to create 4 subcutaneous pockets, two on each side of the 
midline. An alginate bead containing growth factors or a control solution was implanted 
in the subcutaneous space. The wound was closed using resorbable sutures (Ethicon 5-0 
polydioxanone sutures). After 7 days, the animals were sacrificed. To perform en-face 
imaging of the gels, the full thickness skin of the entire dorsal surface was removed and 
mounted on a dissection tray. The alginate gels were then imaged macroscopically and 
gels along with the surrounding skin tissue were flash frozen in liquid N2-cooled 
isopentane for subsequent analysis. 
4.2.7 Histology and Staining  
Eight-micron thick sections were obtained from frozen tissues using the Leica 
CM 1850 Cryotome equipped with steel knife. For H&E staining, the sections were fixed 
in 10% formalin for 10 minutes, washed in 1X PBS for 5 minutes and then air dried at 
60°C for 1h. The standard H&E protocol [96] was then followed and sections imaged 
with an upright compound microscope. Briefly, after a wash in distilled water, the 
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sections were stained in Harris Hematoxylin solution for 8 minutes. This was followed by 
a 5-minute wash in running tap water to get rid of excess hematoxylin. Then the slides 
were put in differentiation buffer for 30 seconds and quickly washed under running tap 
water for 1 minute. This was followed by staining in Bluing reagent for 1 minute, a wash 
in running tap water for 5 minutes, a rinse in 95% alcohol, a counterstain in Eosin 
solution for 1 minute, dehydration through 95% alcohol, and finally two changes of 
absolute alcohol, 5 minutes each. The stains were cleared in two changes of xylene, 5 
minutes each, and mounted with xylene-based mounting medium and cover glasses. 
The slides with the sections on them were also stained by standard Movat’s 
Pentachrome staining procedure [97] to investigate the anatomical features. The slides 
were placed in a slide rack and mordanted with Bouin’s fluid for 1 hour at 50°C. Traces 
of Picric acid were removed by washing in running water for 2 minutes. They were then 
stained in 1% Alcian Blue for 20 minutes and washed in distilled water by dipping 5 
times in the bucket. Then the slides were placed in Alkaline alcohol for 10 minutes at 
56°C. Slides were washed in running water for 2 minutes. Then they were stained in 
Orcein-Verheoff Hematoxylin solution for 15 minutes and washed in distilled water 
twice by dipping and then running tap water rinses. This step is crucial as it stains for 
collagen and elastin. This was followed by staining in the Woodstain Scarlet-Acid 
Fuchsin for 2.5 minutes, 0.5% Acetic acid for 30 seconds, 5% Phosphotungstic acid for 
7.5 minutes, 0.5 Acetic acid for 30 seconds and ultimately, 3 washes of ethanol 1 minute 
each. The slides were then stained with Alcoholic Saffron for 8 minutes and 2 washes of 
ethanol with three dips each. To clean the slides at the end, two 30-second dips in Xylene 
were used, and then mounted with cover glass and Cytoseal™. 
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For immunohistochemical staining, the sections were fixed in 4% 
paraformaldehyde for 5-10 minutes, blocked with 25% FBS for 45 minutes and then 
exposed to a 1:50 dilution of primary antibody (refer Table 3.2 for details) overnight at 
4°C. The following day, samples were washed three times with PBS and treated with a 
1:500 dilution of secondary antibody conjugated to a fluorescent marker (refer Table 3.2 
for details) for 2h at room temperature. The slides were rinsed with PBS and cover glass 
mounted using DAPI containing anti-fade mounting medium (Vector Labs). Imaging was 
performed with the Zeiss Axiovert or Leica SP2 AOBS, and images were analyzed using 
Photoshop and Metamorph. 
4.2.8 Statistical Analysis  
All results were shown as mean + SEM. When comparing only two groups, 
Student’s t-test was used.  A two tailed probability with p-value, p < 0.05 was considered 
statistically significant. 
 
4.3 RESULTS 
4.3.1 Characterization of Syndesomes 
We created syndesomes by isolating the recombinant protein (Figure 4.3) and 
combining it with liposomes using the detergent extraction method. We confirmed the 
integrity of the liposomes by performing a TEM analysis of ultrathin sections of the 
syndesomes (Figure 4.5). In addition, we measured the size distribution of the isolated 
recombinant protein and the syndesomes following liposomal embedding and dialysis. 
This analysis demonstrated that the recombinant protein in isolation had significant self-
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association and separated into three distinct peaks, likely representing three 
oligimerization states (Figure 4.4A). The syndesomes exhibited a single peak 
corresponding to the liposome diameter of ~400 nm. (Figure 4.4B) To obtain a slow and 
sustained release of FGF-2 and syndesomes, we encapsulated them in an alginate gel. 
Measurements of the release of growth factor and lipid from the gel revealed that it is 
dependent on the crosslinking density and shape of the hydrogel. While a 4% alginate 
bead released all the contents by 8 days, the 2% alginate disk needed only 5 days to 
disintegrate. The release profiles of FGF-2 were similar for both the FGF-2 alone and 
FGF-2 with syndesomes.  
 
 
Figure 4.3 Western blot after SDS PAGE gel run showing three lanes - Ladder (1), 
negative un-transfected control (2), and cell lysate of transduced cells (3). 
The nitrocellulose membrane was incubated in syndecan-4 antibody. 
Purified syndecan-4 protein (black arrow) and some degraded or 
extracellular domain of syndecan-4 (lower band) show up on the developed 
blot.  
  1         2         3 
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Figure 4.4 Dynamic light scattering results for syndecan-4 protein in solution (A) and 
syndesomes (S4PL) in solution (B). 
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Figure 4.5 Cryo-TEM image showing the syndesomes in a cross sectional view.  
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4.3.2 Overcoming Growth Factor Resistance in ob/ob Mouse Model  
The failure of many human trials for growth factor therapies has highlighted the 
need for new treatments that can overcome growth factor resistance [44]. Our finding of 
decreased cell surface co-receptors in a diseased state suggested that this could be an 
amenable target for increasing growth factor activity in disease states. We have recently 
shown that growth factor activity can be enhanced in healthy animals by co-delivering 
them with sdc-4 embedded in a liposomal carrier [67].  
Here, we microencapsulated syndesomes in an alginate carrier and examined 
whether this treatment could overcome disease-induced resistance to growth factor 
stimulation. We subcutaneously implanted gels containing PBS, FGF-2, and FGF-2 with 
syndesomes in ob/ob mice after 15 weeks of high fat diet. The addition of syndesomes 
markedly enhanced vascularity (Figure 4.6A,B) as well as the vascularized layer 
thickness (Figure 4.7A,B). We observed similar alterations for the vascularized layer 
thickness for both WT and ob/ob mice. PECAM staining of the sections confirmed that 
the cellular layer around the gels was indeed vascular (Figure 4.9). We also performed 
Movat’s Pentachrome Staining on the tissue sections that confirmed the cellular nature of 
the tissue surrounding the implant (Figure 4.8). Together these studies support that the 
delivery of the co-receptor proteins, which are reduced in the diseased tissue, can 
enhance the growth factor response and significantly overcome the growth factor 
resistance in this animal model of diabetes and obesity. 
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Figure 4.6 Alginate gels harvested after 7 days and macroscopically imaged (A). 
Vascularity around the gel was determined for the macroscopic images 
using Metamorph (B). Panel A - size bar = 3mm. Mag. size bar = 1mm. 
*Statistically different from WT group (p < 0.05). n=5. Adapted from [89]. 
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Figure 4.7 The alginate gels along with the skin, frozen, sectioned, and H&E stained 
(A). The thickness of the vascular layer was quantified by analyzing the 
H&E stained images on Metamorph (B). Panel A - size bar = 1mm. Mag. 
size bar = 250μm. *Statistically different from WT group (p < 0.05). n=5. 
Adapted from [89]. 
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Figure 4.8 Movat’s Pentachrome staining of the sections of alginate gels with PBS, 
FGF-2 and syndesomes with FGF-2 (S4PL+FGF-2). The gels were 
harvested after 7 days frozen, sectioned, and stained as shown here. Size bar 
= 1mm. Mag. size bar = 250μm. n=5. Adapted from [89]. 
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Figure 4.9 Sections immunostained with anti-PECAM antibody and imaged with an epifluorescence microscope. Size bar = 
250μm. *Statistically different from ob/ob group (p < 0.05). n=5. Adapted from [89]. 
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4.4 DISCUSSION 
In our studies aimed at overcoming growth factor resistance, we focused our 
therapeutic strategy on restoring sdc-4 as a means for enhancing angiogenesis in the 
diseased state. Syndecan-4 is known to regulate FGFR-1 signaling and macropinocytosis 
[67, 107]. It also has pro-angiogenic activities through interactions with thrombospondin-
1 [108] and regulates FGF-2 signaling [109]. Due to the continued challenges in applying 
exogenous gene delivery in humans [55], we developed a strategy to deliver co-receptors 
that are absent due to disease by using recombinant proteins embedded in a liposomal 
carrier [67]. Our major aim here was to test whether exogenously delivered growth factor 
co-receptors could overcome growth factor resistance that is caused by loss of co-
receptors. In our studies, the syndesomes were highly effective in enhancing FGF-2 
stimulation in mice with disease. Our findings suggest a unique approach for combating 
growth factor resistance at the level of co-receptor/receptor loss and illustrate an example 
of the efficacy of this strategy in an animal disease model. Liposomal co-receptor 
therapies may have the potential to treat many diseases in which the enhancement or 
reduction of signaling is caused by the loss of a co-receptor. Sdc-1 and nrp-1 (other co-
receptors that were lost due to diseased state) would be appealing targets to explore for 
the development of additional therapeutics.  
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4.5 CONCLUSIONS 
Briefly, we have shown that it is possible to identify deficiencies in growth factor 
signaling pathways in diseased tissues. We found that the diseased tissue is unable to 
make appropriate amount of protein in spite of higher gene expression levels and thus 
does not respond to the diseased state. Further, we have found that replenishing isolated 
components of the signaling cascade in an appropriate delivery system can markedly 
enhance in vivo response to growth factor treatments. These preliminary experiments 
demonstrate the feasibility and potential of this unique and powerful approach to 
increasing the efficacy of growth factor-based therapies in the clinical setting. However, 
much work remains in understanding and applying this approach to human disease.  
Diabetes and associated peripheral diseases are a worldwide problem with no 
long-term solutions. To treat ischemia and non-healing foot ulcers, we aim to better 
understand the mechanisms acting in diseased patients and to develop a novel injectable 
gel for enhancing growth factor therapies. The basic findings and techniques developed 
in this thesis represent a paradigm shift in how growth factor signaling pathways are 
approached from a therapeutic perspective. While this work focuses on ischemia and 
vascular disease, growth factors are intimately involved in the mechanisms of many 
diseases including cancer growth and metastasis, wound healing and the immune 
response to infection. Thus, the innovative techniques we will develop will have a broad 
impact on the understanding and treatment of diverse disease states.  
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Chapter 5: Syndesomes Enhance Revascularization in Ischemic Muscle 
of Diseased and Diabetic Mouse 
 
5.1 INTRODUCTION 
Peripheral vascular disease (PVD) has serious clinical consequences for patients 
including atypical pain, intermittent claudication, foot ulcers, and ultimately, an increased 
risk for limb amputation and cardiovascular mortality [4]. The current clinical standard of 
care for PVD includes physical therapy, pharmacological interventions, endovascular 
stent placement and surgical bypass of stenosed arteries [9]. While these methods are 
used to treat the symptoms on a short-term basis, presently no durable, long-term 
treatment options exist in clinical use for patients with PVD. The diabetic population is 
particularly plagued by conditions caused by PVD, with high prevalence of foot ulcers 
and lacerations. Ankle-brachial index (ABI) screens have determined that the prevalence 
of PVD among diabetics is approximately 20-30% [110]. Although 50% of the patients 
are asymptomatic, their prognoses steadily worsens with time [4]. The 5-year mortality 
rate among patients with symptomatic PVD is about 20% [25]. Of those patients who 
develop critical limb ischemia, as many as 25% require amputation, increasing the 
mortality rate to 25% [26]. Type-2 diabetes has become a global epidemic afflicting 
about 347 million people and is responsible for the deaths of about 4.6 million people 
worldwide, according to the WHO. Since the risk of PVD is significantly increased in the 
presence of diabetes, it is essential to find viable treatment options for PVD. The ideal 
solution is to revascularize ischemic tissue and restore it to a healthy state of blood flow.  
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Several studies have examined the effectiveness of growth factors and associated 
genes, proteins, and cells for treating peripheral ischemia. The TRAFFIC trial, a phase I, 
randomized and double-blinded trial using delivery of bFGF-2, found no difference 
between placebo and double dose of treatments despite promising early studies [10, 11]. 
Similarly, a phase I/IIa trial for the delivery of hepatocyte growth factor plasmid found 
no significant benefit in comparison to placebo [14]. Clinical trials of implantation of 
bone marrow mononuclear cells have also shown no considerable improvement 
compared to present revascularization standards [110]. None of the existing studies have 
shown any statistically significant benefit over placebos.  
The overarching goal of my thesis is to overcome the disease-induced growth 
factor resistance by delivering the missing growth factor co-receptors to revitalize the 
diseased tissue to a healthier phenotype. In the present chapter, we describe the 
experiments performed to test the syndesomal therapy to revascularize ischemic muscle 
in a diseased diabetic mouse model.  
 
5.2 MATERIALS AND METHODS 
5.2.1 Animal Model 
All animal experiments were performed with the approval of the Institutional 
Animal Care and Use Committee (IACUC) of University of Texas at Austin and in 
accordance with NIH guidelines “Guide for Care and Use of Laboratory Animals” for 
animal care. All the animal experiments were performed on a diabetic, obese and 
hyperlipidemic mouse model (ob/ob). They were fed for 15 weeks with a high-fat diet 
before being utilized for the surgeries. This was done to recapitulate the human diseased 
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condition more closely and simulate the physiological response of an obese diabetic 
person. The animals were sacrificed 14 days after the surgery and the tissues were used 
for histology and staining. 
5.2.2 Implant Preparation 
Spherical alginate beads encapsulating all the treatment groups were fabricated 
for the hind-limb ischemia surgery. Equal volumes of 4% sodium alginate (Sigma™) 
solution and 0.85% NaCl (Sigma™) solution were mixed and the syndesomes and/or 
growth factors were added to it. The solution was extruded through a syringe with an 18G 
needle into a 1.1% CaCl2 solution and cross-linked for 1 hour at 4°C. About 3.6μg of 
FGF-2 and 0.34μg of syndecan-4 protein in the S4PL + FGF-2 group, and 3.6μg of FGF-
2 in the FGF-2 group were encapsulated in the gels that were implanted in each mouse. 
5.2.3 Hind Limb Ischemia Surgical Model 
Mice were anaesthetized using 3% isoflurane gas. The left hind limb was shaved 
and surgically prepared with three swabs each of Betadine and 70% ethanol. A skin 
incision was made on the medial side of the thigh of the left hind limb, and the femoral 
artery was dissected free from the vessel bundle, without damaging the vein and nerve 
(Figure 5.1). The left femoral artery was then ligated with two sutures using 3-0 woven 
silk, just distal to the inguinal ligament. Alginate beads encapsulating syndesomes and/or 
FGF-2 were applied directly to the region surrounding the femoral artery (Figure 5.2).  
The wound was closed using resorbable sutures (5-0 vicryl). The animals were closely 
monitored and were administered with buprenorphine analgesic medication (0.1 mg/kg at 
12-24 hour intervals) for two days following surgery. The animal’s limb perfusion was 
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monitored daily using laser speckle imaging as described below. At day 14, mice were 
euthanized to harvest the gastrocnemius and quadriceps muscle of both ischemic and 
contralateral limb. Tissues were snap frozen in liquid N2-chilled isopentane for further 
use.  
 
Figure 5.1 Schematic diagram showing left femoral artery ligation procedure to induce 
ischemia in the hind limbs of the mice. The alginate gels are implanted at 
the incision site and stitched with 5-0 sutures. 
 
 
Figure 5.2 Macroscopic image of the left hind limb with ligated femoral artery and 
alginate gels in the incision site. The retractors keep the incision in place to 
facilitate the surgery. 
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5.2.4 Laser Speckle Contrast Imaging 
The Laser Speckle Contrast Imager (LSCI) maps the tissue blood flow by the shift 
in laser light frequency due to the motion of blood [111] (Figure 5.3). This was used for 
serial noninvasive physiological evaluation of neovascularization by the animal’s blood 
perfusion that was monitored at the time points. The blood perfusion in the ischemic limb 
(hind-limb ischemia surgery) was quantified relative of the contralateral control limb. 
The blood perfusions in the wounds (excisional wound surgery) were quantified relative 
to the wound with control gel implanted in the wound bed. 
 
 
Figure 5.3 The raw speckle image converted into a speckle contrast image and then 
into a speckle heat map image showing relative blood flow (left). Non-
invasive imaging of ischemic feet after the femoral ligation surgery showing 
blood perfusion in the feet relative to uninjured feet. The heat map bar 
shows the relative flow conditions for different colors (right). 
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5.2.5 Histology, Immunostaining, and Quantification 
The muscle tissues were embedded in paraffin and 6μm sections were made using 
a microtome. H&E staining was performed for anatomical feature characterization, as 
described: the sections were de-paraffinized with two changes of xylene, 10 minutes 
each. They were re-hydrated in two changes of absolute alcohol for 5 minutes each, 
followed by 95% alcohol for 2 minutes and 70% alcohol for 2 minutes. The slides were 
then washed in 1X PBS for 5 minutes and placed on the slide warmer at 60°C for 1 hour. 
After a brief wash in distilled water, the sections are stained in Harris Hematoxylin 
solution for 8 minutes. This was followed by a 5-minute wash in running tap water to get 
rid of excess hematoxylin. Then the slides were put in differentiation buffer for 30 
seconds and quickly washed under running tap water for 1 minute. This was followed by 
staining in Bluing reagent for 1 minute, a wash in running tap water for 5 minutes, a rinse 
in 95% alcohol, counterstain in Eosin solution for 1 minute, dehydration through 95% 
alcohol, two changes of absolute alcohol - 5 minutes each. Finally, the stains were 
cleared in two changes of xylene, 5 minutes each, and mounted with xylene-based 
mounting medium and cover glasses. 
The slides were then Movat’s stained to stain the various components in the tissue 
to probe more of the anatomical features. The sections were de-paraffinized and hydrated 
as described above. The slides were placed in a slide rack and mordanted with Bouin’s 
fluid for 1 hour at 50°C. Traces of Picric acid were removed by washing in running water 
for 2 minutes. They were then stained in 1% Alcian Blue for 20 minutes and washed in 
distilled water by dipping 5 times in the bucket. Then the slides were placed in Alkaline 
alcohol for 10 minutes at 56°C. Slides were washed in running water for 2 minutes. Then 
they were stained in Orcein-Verheoff Hematoxylin solution for 15 minutes and washed in 
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distilled water twice by dipping and then running tap water rinses. This step is crucial 
since it stains for collagen and elastin. This was followed by Woodstain Scarlet-Acid 
Fuchsin stain for 2.5 minutes, 0.5% Acetic acid for 30 seconds, 5% Phosphotungstic acid 
for 7.5 minutes, 0.5 Acetic acid for 30 seconds, and ultimately, 3 ethanol washes of 1 
minute each. The slides were then stained with Alcoholic Saffron for 8 minutes and 2 
ethanol washes with three dips each. To clean the slides at the end, two 30-second dips in 
Xylene were used, and then mounted with cover glass and Cytoseal™. 
 
They were also immunostained using the Envision+ Dual Link Kit (Dako™) for 
M1 macrophage marker (CD86), M2 macrophage marker (CD163), and endothelial cell 
marker (von Willebrand factor). The slides were warmed for 10 minutes at 60°C on a 
slide warmer. Then they were de-paraffinized as described above. The next step in the 
protocol was vital and had to be carefully optimized for the fatty mouse tissues that were 
stained. The slide rack was placed in a bucket with Antigen Retrieval Solution (Dako) 
and placed in the microwave (1250W) for 2 minutes and 40 seconds. Then the bucket is 
placed in a water batch maintained at 80°C for 3 hours. This reduces the background 
staining significantly. The slides were cooled in solution for 20 minutes and washes in 
PBS twice for 5 minutes each. Then they were blocked in 20% normal fetal bovine serum 
in PBS for 45 minutes at room temperature. The slides were then washed two times for 5 
minutes in PBS and a circle drawn around the section with a hydrophobic pen. The 
sections were peroxide blocked with dual enzyme block solution (Dako) and incubated 
for 30 minutes. It was followed by 3 washes in PBS for 5 minutes each. After that, the 
primary antibody in antibody diluent (Dako) was applied to the sections and incubated at 
4°C for overnight. On the following day, the sections were washed in PBS thrice and then 
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the peroxidase labeled polymer (HRP) was added and incubated for 30 minutes at room 
temperature. Nine washes were done after that with PBS and waiting for 5 minutes every 
3 washes. In the meantime, the DAB+ solution was prepared and added to the section. 
The incubation period was optimized according to the intensity of staining. After 3 
washes in PBS, the slides were stained in Mayer’s hematoxylin for 3 minutes. Finally 
they were washed in distilled water three times, mounted with crystal mount, and sealed 
with the cover glass and Cytoseal™. 
5.2.6 Statistical Analysis 
The results were depicted as mean + SEM. We used n=10 for hind limb ischemia 
surgery model. When comparing only two groups, Student’s t-test was used. A two tailed 
probability with p-value, p < 0.05 was considered statistically significant and pairing was 
taken into consideration wherever necessary. 
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5.3 RESULTS 
5.3.1 Syndesomes Restore Blood Perfusion in Ischemic Hind Limb of ob/ob Mice 
We created hind limb ischemia in ob/ob mice through the complete ligation and 
subsequent removal of a portion of the femoral artery between the ties. This model 
creates ischemia in one of the limbs to simulate peripheral ischemia due to occlusive 
vascular disease. A major problem in diabetic patients is a lack of perfusion in the lower 
limb leading to poor healing outcomes [112]. We monitored the blood perfusion in the 
feet using laser speckle contrast imaging and found that by day 7, there were significant 
differences increased between the FGF-2 group and the syndesomes with FGF-2 group. 
The differences continued to increase with time and at day 14 the syndesome with FGF-2 
group had about 86% recovery compared with about 50% recovery in the FGF-2 group 
(Figure 5.4). Thus, there was a steady increase in blood flow in the ischemic limbs 
relative to the contralateral limb. To confirm that the increase in perfusion was due to 
neovascularization in the treated tissue, we performed immunostaining for blood vessels 
(von Willebrand Factor). We observed a significant increase in the number of smaller 
vessels and larger vessels in both calf muscle and thigh muscles (Figure 5.5). 
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Figure 5.4 Syndesomes with FGF-2 significantly improve blood flow in the ischemic 
feet compared with FGF-2 alone. Upper panel shows laser speckle contrast 
images of the uninjured contralateral limb (Ctrl) and injured ischemic limb 
(Isch) over the course of time for both the treatments. Lower graph is the 
quantification of blood flow relative to the contralateral feet. *Statistically 
different from FGF-2 group (p < 0.05). n=10.  
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Figure 5.5 Syndesomes with FGF-2 dramatically enhance angiogenesis in both the 
quadriceps (thigh) and gastrocnemius (calf) muscles. The sections of the 
tissue were immunostained for the endothelial marker von Willebrand 
factor. Inset shows 3X-enlarged image with positive staining. Quantification 
of vessels shows dramatic up-regulation of vessels per field of view due to 
presence of syndesomes. Size bar is 250μm. Inset is 3X magnified. 
*Statistically different from FGF-2 group (p < 0.05). n=10. 
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5.3.2 Syndesomes Minimize Ischemic Changes in the Muscle fibers  
Following femoral artery ligation, there can be loss/alterations of muscle fibers 
due to ischemia. We found in the H&E stains of the muscle sections that, mice treated 
with syndesomes and FGF-2 had significantly reduced number of muscle fibers 
exhibiting ischemic damage compared with the FGF-2 alone treatment group (Figure 
5.6). The FGF-2 alone group had areas of gross focal and regional fiber necrosis, 
degeneration and loss of tissue structure. The loss in the muscle fibers was most likely 
due to ischemic and hypoxic condition that leads to degeneration of the fibers. This trend 
was observed in both calf and thigh muscles. We confirmed that the holes in the fibers 
were not freezing artifacts by comparing to the non-ischemic contralateral control limb 
samples harvested from the thigh and calf muscle. Another noticeable difference between 
the two groups was the migration of the nucleus to the center of the fiber. This is the first 
step for muscle repair [113] and was more predominant in the syndesome with FGF-2 
group compared with the FGF-2 alone group.  
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Figure 5.6 H&E stained images of thigh and calf muscle tissue at day 14 and 
quantification of the number of ischemic defects in the muscle fibers per 
unit area. Size bar is 250μm. Inset is 3X magnified. *Statistically different 
from FGF-2 group (p < 0.05). n=10. 
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5.3.3 Syndesomes Enhance Wound-Healing Macrophage Phenotype 
We then examined whether syndesomes with FGF-2 alter the immunological 
response to ischemia when compared with FGF-2 treatment alone. The muscle tissue 
sections were immunostained for the inflammatory M1 macrophage marker (CD86). We 
quantified the ratio of positive staining to the total nucleus area. We found comparable 
M1 levels in calf and thigh muscle for both treatment groups (Figure 5.7). We also 
immunostained for alternatively activated M2 macrophages (CD163), which are 
considered to possess wound-healing characteristics. There was a significant increase in 
M2 positive cells in the cellular infiltrate surrounding both calf and thigh muscles in the 
S4PL+FGF-2 group compared with FGF-2 alone (Figure 5.8).  Another major point to 
note here is that the sections were 6μm thick and so the stained images for M1 and M2 
are from the same location. Keeping the background staining intensity same and 
superimposing the images, we found intense staining for M2 compared with M1 
macrophages for the same cells. Hence the same cell is expressing more CD163 receptors 
compared with CD86 receptors. We think that over time, the macrophages would keep 
shifting towards the M2 phenotype to heal the wound effectively. It is now generally 
accepted that macrophages are inherently plastic in nature and that they switch between 
many phenotypes seamlessly [114]. Therefore, we can surmise that our therapy is 
probably driving the same macrophage cells towards a more wound-healing phenotype 
and away from inflammatory features.  
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Figure 5.7 Muscle tissue from thigh and calf sectioned, and immunostained for 
inflammatory M1 macrophage marker (CD86) (left). Quantification of 
number of positive cells per unit nuclear (right). Size bar is 500μm. Inset is 
3X magnified. n=10. 
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Figure 5.8 Sections from calf and thigh muscles stained for the alternatively activated 
M2 macrophage marker (CD163) (left). Quantification of positive staining 
(right). Size bar is 500μm. Inset is 3X magnified. *Statistically different 
from FGF-2 group (p < 0.05). n=10. 
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5.4 DISCUSSION 
In this study, we demonstrated the efficacy of syndesome treatment for 
therapeutic angiogenesis in a clinically relevant diabetic hyperlipidemic mouse model. 
We believed that the resistance to growth factor therapy [89] is a significant obstacle to 
growth factor therapeutics and may underlie the equivocal or mild results that growth 
factor therapies have achieved in clinical trials in patients with complex disease in 
contrast to healthy animals. Thus, we hypothesize that the current approach of delivering 
only growth factors or growth promoting genes is fundamentally flawed in that it does 
not account for the alterations in tissue responsiveness to these factors due to metabolic 
disease. 
Our overarching goal was to ensure the effectiveness of the therapy in a diseased 
environment, not just normal tissue. We found that ischemic limbs completely recovered 
within 14 days when treated with FGF-2 and syndesomes, compared with only partial 
recovery when treated with FGF-2 only. Histological analyses confirmed a significant 
increase in the number of blood vessels in both gastrocnemius and quadriceps muscles. 
Ischemic fibers in syndesome treatment group were also negligible. And most 
importantly, the therapy drives the macrophages towards an alternatively activated M2 
phenotype.  
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5.5 CONCLUSIONS 
Taken together, our studies support that co-delivery of syndecan-4 with FGF-2 
significantly enhances revascularization in the ischemic hind limb in a clinically relevant 
diseased mouse model. Our studies demonstrate a significant increase in blood flow in 
the ischemic hind limb compared with the contralateral, which is due to enhanced 
therapeutic angiogenesis. There was also remarkable increase in alternatively activated 
M2 macrophage phenotype that favors wound healing in the tissue. This study is a 
notable first step towards finding efficient long-term solutions for patients suffering from 
myocardial or peripheral ischemia. 
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Chapter 6: Syndesomes Significantly Increase Cutaneous Wound 
Healing in a Diabetic ob/ob Mouse Model 
 
6.1 INTRODUCTION 
 Type-2 diabetes is being called the “epidemic of our generation” and it is 
estimated by the World Health Organization that 347 million people suffer from diabetes 
mellitus worldwide [45, 46]. Diabetic neuropathy and microvascular angiopathy are 
common complications of diabetes and contribute to a 12-25% lifetime risk of developing 
chronic ulcers [51]. Specifically, diabetic foot ulcers are responsible for 25-50% of the 
total cost of diabetes treatment [52] and are the most common cause for limb amputations 
in the United States [53]. Diabetic ulcers are a complex clinical problem requiring a 
multifaceted treatment plan with standard therapeutic components including debridement 
of necrotic tissue, offloading, infection control, surgical revascularization, and limb 
elevation/compression [18, 19]. Unfortunately, these treatments routinely fail, leaving 
patients with chronic ulcers, and enhanced risk for limb amputation.  Peripheral vascular 
disease (PVD) patients also suffer from non-healing wounds and ulcers due to reduced 
blood perfusion in lower extremities. PVD has a prevalence of 12-20% in the population 
65 years and older in the US [6] and affected 202 million people worldwide in 2010 [1]. 
The increase in prevalence of strong risk factors like smoking, hypertension, obesity and 
metabolic syndrome indicate that the population affected by non-healing chronic ulcers 
will continue to grow in the future. 
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A number of advanced wound dressings have been used to attempt to heal these 
ulcers once standard care has failed. A host of wound dressing materials have been used 
to improve wound healing including natural biological materials such as honey [115] and 
chitosan [116] as well as modified materials such as silver-containing alginate dressings 
[117]. Bioactive dressings are an appealing strategy that has great potential to control and 
enhance wound healing. The most prevalent approaches to bioactive dressings can be 
broadly classified into the categories of local delivery of growth factors [118], delivery of 
therapeutic genes [119], or delivery of cells with the potential to enhance healing [120]. 
Of these three, only growth factors have been tested in large clinical trials perhaps due to 
the safety and logistical challenges for gene or stem cell therapy. Growth factor therapies 
have, for the most part, met with limited level of success and the majority of studies are 
small- to mid-sized clinical trials that often track only complete wound closure but not 
percent closure or time to closure, leaving the clinical recommendation for these 
therapies unclear. The only approved clinical growth factor treatment for chronic wounds 
is recombinant PDGF-BB (Becaplermin), and while approved by the FDA, it has 
received mixed success in clinical trials on chronic ulcers [121-123]. FGF-2 and EGF 
have either shown no improvement or shown only moderate benefits in small clinical 
trials [124-126]. Thus, while clinical trials have shown that growth factor therapies are 
safe and well tolerated by patients, there is a pronounced need to improve the efficacy of 
these treatments to maximize the benefit of these therapies and make them cost effective 
for our healthcare system.  
The development of effective growth factor therapies would have a profound 
effect on the clinical treatment of diabetic patients with chronic ulcers and many other 
patient groups with difficult to heal wounds (e.g. pressure ulcers in the elderly, venous 
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ulcers, and infected wounds). Our proposed studies are focused on enhancing the 
effectiveness of FGF-2 and have a great potential to also be effective with other heparan-
sulfate dependent growth factors including VEGF-A and HB-EGF. Thus, our work is 
poised to contribute to this field by developing new technology to enhance closure in 
healing-resistant wounds and has great potential for use in many other disorders that 
would benefit from effective growth factor therapies.  
 
 
Figure 6.1 Overall goal of this chapter is to engineer alginate dressings that enhance 
wound healing in chronic wounds. 
In the present chapter, we demonstrate the efficacy of syndesomal therapy in the 
context of full thickness wounds with silicone splints around them to simulate human-like 
wound healing, in a clinically pertinent diabetic and diseased mouse model (Figure 6.1).  
 
6.2 MATERIALS AND METHODS 
6.2.1 Animal Model  
All animal experiments were performed with the approval of the Institutional 
Animal Care and Use Committee (IACUC) of University of Texas at Austin and in 
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accordance with NIH guidelines “Guide for Care and Use of Laboratory Animals” for 
animal care. All the animal experiments were performed on a diabetic, obese, and 
hyperlipidemic mouse model (ob/ob). They were fed for 15 weeks with a high-fat diet 
before being utilized for the surgeries. This was done to recapitulate the human diseased 
condition more closely and simulate the physiological response of an obese diabetic 
person. The animals were sacrificed 2, 5, or 14 days after the surgery and the tissues were 
used for histology, staining, flow cytometry, and other analyses. 
6.2.2 Implant preparation  
Alginate gels were fabricated as 6.5mm-diameter disks for the excisional wound 
surgery. Equal volumes of 4% sodium alginate (Sigma™) solution and 0.85% NaCl 
(Sigma™) solution were mixed and the syndesomes and/or growth factors were added to 
it. A custom-made high throughput mold was used to make the exact shape so that it fits 
the wounds (Figure 6.2). The gels were then cross-linked in 1.1% CaCl2 for 1 hour at 
4°C. 5μg of FGF-2 and/or 0.5μg of syndecan-4 protein were encapsulated in the gel, 
according to the sample (control, FGF-2, S4PL, or S4PL+FGF-2) in each disk implanted. 
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Figure 6.2 Custom made high throughput mold for alginate disk fabrication for 
implantation in the mouse excisional wound model. (A) The sterile metal 
piece was placed in the biosafety cabinet and a filter paper soaked with 
1.1% CaCl2 was placed on it. The metal mold was put on top of the filter 
paper. The 4% alginate solution was added to the wells drop-wise and then 
covered with another mold wrapped in a wet filter paper. (B) More CaCl2 
solution was added to the setup and clamped on both sides to keep it in 
place. The entire setup was moved to the cold room to keep the gels at 4°C. 
(C) After 1 hour of incubation we have the cross-linked alginate disks that 
are 6.5mm in diameter and fits the wound perfectly. 
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6.2.3 Excisional Splinted Wound Healing Model  
The methods followed in the experiments were based on the protocol outlined in 
the paper by Wang et.al [127] and shown in the Figure 6.3 and 6.4. A sterile 5mm biopsy 
punch was used to outline a pattern of four wounds, two on either side of the midline on 
the dorsum of the mouse. A toroidal-shaped splint was fashioned from a 0.5mm thick 
silicone sheet and was placed so that the wound was centered within the splint. 6-0 nylon 
sutures and instant glue were used to fix the splint to the skin and to ensure position and 
no wound contraction. Alginate gel disks of 5mm-diameter encapsulating syndesomes 
and/or FGF-2 were then applied directly to the region of the open wound. Tegaderm was 
used to cover all the wounds. Macroscopic images of wounds were taken on day 0, 7, and 
14; which were later used for wound closure quantification. The animals were euthanized 
at day 14 and the wound was biopsied with a 10mm biopsy punch. The tissues were snap 
frozen in liquid N2-chilled isopentane and used for further analysis. 
 
Figure 6.3 Schematic diagram showing the splinted excisional wound model procedure 
in ob/ob mice. 
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Figure 6.4 The steps followed for the excisional wound model surgery. The dorsal 
surface of the ob/ob mouse is depilated. Full thickness wounds are made on 
the dorsal surface, a silicone splint is glued around the wound to prevent 
contraction and the splint is stitched to keep the splints in place. The 
alginate gel is finally implanted in the open wound and covered with a 
transparent wound dressing Tegaderm. 
 
6.2.4 Flow Cytometry 
The wounds (day 2 and 5) were excised out using a 10mm sterile biopsy punch 
and cut from the center into two disc shaped pieces. Half of the tissue was used for 
cryosectioning and histology. The other half was digested [128] in an enzyme cocktail 
and used for flow cytometry experiments. The single cell suspension derived from the 
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wound tissue was maintained at 106 cells/ml in the FACS staining buffer (BD 
Biosciences). The samples were blocked with 1μg/ml (final concentration) of Rat IgG2b 
that blocks the Fc receptor (BD Biosciences) for 30 minutes on ice. The cells were then 
stained with all the following antibodies for 30 minutes on ice: anti-mouse F4/80 PE-Cy7 
(eBiosciences), anti-human CD206 FITC (BD Biosciences) and anti-mouse CD86 Biotin 
Ig (BD Biosciences). Two washes were performed with FACS staining buffer. The PerCP 
streptavidin antibody was used to stain the samples for another 30 minutes on ice. The 
samples were finally washed twice with the FACS staining buffer. The samples were 
fixed with 500μl of Cytofix buffer (BD Biosciences) and resuspended in 1ml buffer and 
stored at 4°C. All the samples were run together on the BD LSRFortessa™ machine and 
the data were later analyzed using the FlowJo analysis software. 
6.2.5 Histology and Staining  
The wound tissues were embedded in paraffin and 6μm sections were made using 
a microtome. The sections were de-paraffinized with two changes of xylene, 10 minutes 
each. They were re-hydrated in two changes of absolute alcohol, 5 minutes each, 
followed by 95% alcohol for 2 minutes and 70% alcohol for 2 minutes. The slides were 
then washed in 1X PBS for 5 minutes and placed on the slide warmer at 60°C for 1 hour. 
After a brief wash in distilled water, the sections are stained in Harris Hematoxylin 
solution for 8 minutes. This was followed by a 5-minute wash in running tap water to get 
rid of excess hematoxylin. Then the slides were put in differentiation buffer for 30 
seconds and quickly washed under running tap water for 1 minute. This is followed by 
staining in Bluing reagent for 1 minute, a wash in running tap water for 5 minutes, a rinse 
in 95% alcohol, counterstain in Eosin solution for 1 minute, dehydration through 95% 
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alcohol, two changes of absolute alcohol, for 5 minutes each. Finally, the stains are 
cleared in two changes of xylene, 5 minutes each, and mounted with xylene-based 
mounting medium and cover glasses. 
The slides were Movat’s stained to stain the various components in tissue to probe 
the anatomical features. The sections were de-paraffinized and hydrated as described 
above. The slides were placed in a slide rack and mordanted with Bouin’s fluid for 1 hour 
at 50°C. Traces of Picric acid were removed by washing in running water for 2 minutes. 
They were then stained in 1% Alcian Blue for 20 minutes and washed in distilled water 
by dipping 5 times in the bucket. Then the slides were placed in Alkaline alcohol for 10 
minutes at 56°C. Slides were washed in running water for 2 minutes. Then they were 
stained in Orcein-Verheoff Hematoxylin solution for 15 minutes and washed in distilled 
water twice by dipping, and then running tap water rinses. This step is crucial since it 
stains for collagen and elastin. This was followed by staining in Woodstain Scarlet-Acid 
Fuchsin stain for 2.5 minutes, 0.5% Acetic acid for 30 seconds, 5% Phosphotungstic acid 
for 7.5 minutes, 0.5 Acetic acid for 30 seconds and ultimately 3 ethanol washes of 1 
minute each. The slides were then stained with Alcoholic Saffron for 8 minutes and 2 
ethanol washes with three dips each. To clean the slides at the end, two 30-second dips in 
Xylene were used and then mounted with cover glass and Cytoseal™. 
They were also immunostained using the Envision+ Dual Link Kit (Dako™) for 
epidermal keratinocyte marker (cytokeratin), M1 macrophage marker (CD86), M2 
macrophage marker (CD163) and endothelial cell marker (von Willebrand factor). The 
slides were warmed for 10 minutes at 60°C on a slide warmer. Then they were de-
paraffinized as described above. The next step in the protocol was vital and had to be 
carefully optimized for the fatty mouse tissues that were stained. The slide rack was 
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placed in a bucket with Antigen Retrieval Solution (Dako) and placed in the microwave 
(1250W) for 2 minutes and 40 seconds. Then the bucket is placed in a water batch 
maintained at 80°C for 3 hours. This reduces the background staining significantly. The 
slides were cooled in solution for 20 minutes and washed in PBS twice for 5 minutes 
each. Then they were blocked in 20% normal fetal bovine serum in PBS for 45 minutes at 
room temperature. The slides were then washed two times for 5 minutes in PBS and a 
circle drawn around the section with a hydrophobic pen. The sections were peroxide 
blocked with dual enzyme block solution (Dako) and incubated for 30 minutes. It was 
followed by 3 washes in PBS for 5 minutes each. After that, the primary antibody in 
antibody diluent (Dako) was applied to the sections and incubated at 4°C for overnight. 
On the following day, the sections were washed in PBS thrice and then the peroxidase 
labeled polymer (HRP) was added, and incubated for 30 minutes at room temperature. 
Nine washes were done after that with PBS, waiting for 5 minutes every 3 washes. In the 
meantime, the DAB+ solution was prepared and added to the section. The incubation 
period was optimized according to the staining intensity obtained. After 3 washes in PBS, 
the slides were stained in Mayer’s hematoxylin for 3 minutes. Finally they were washed 
in distilled water three times, mounted with crystal mount, and sealed with the cover 
glass and Cytoseal™.  
6.2.6 Statistical Analysis 
All the results were shown as mean + SEM. We used n=8 for the excisional 
wound healing model. When comparing only two groups, Student’s t-test was used. A 
two tailed probability with p-value p < 0.05 was considered statistically significant and 
pairing taken into consideration wherever necessary. 
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6.3 RESULTS 
6.3.1 Syndesomes improve wound closure of full thickness wounds 
We tested the effectiveness of our therapy for diabetic wound healing in an ob/ob 
mouse model. These mice develop diabetes, obesity, and have reduced wound closure 
[91]. We created alginate wound dressings that matched the geometry of the wounds 
using a custom-designed mold (Figure 6.2). The integrity of the liposomes in the alginate 
dressing was confirmed using transmission electron microscopy following thin sectioning 
(Figure 4.3). To examine whether syndesomes could enhance wound healing we created 
full thickness wounds of 5mm in diameter on the backs of these mice and attached a 
silicone splint around the wound using glue and sutures to prevent contraction. This was 
important because mice and other rodents have a layer of muscle underneath the skin that 
provides for increased wound contraction after cutaneous injury, which is absent in 
human wound healing. After 7 days, the wounds were photographed macroscopically and 
imaged with laser speckle contrast imager for blood perfusion. The gels were then 
replaced with a new gel with the same treatment and the mice were allowed to heal for 
another 7 days. A macroscopic analysis of wound closure revealed a two-fold decrease in 
wound size after 14 days with the syndesome with FGF-2 treatment in comparison to 
FGF-2 alone (Figure 6.5, 6.6, 6.7).  Histological, morphometric analysis, and staining for 
cytokeratin revealed enhanced re-epithelization in the syndesome with FGF-2 group 
(Figure 6.8, 6.9, 6.10). 
 
 
 
85 
 
Figure 6.5 Macroscopic en-face image of the entire dorsal surface of the mouse at day 
14 with the alginate gels removed and wounds cleaned.  
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Figure 6.6 Wound closure panel. Macroscopic images of the wounds with the silicone 
splints around them at days 0, 7, and 14. 
 
 
Figure 6.7 Quantification of wound closure area for the 4 treatment groups at days 0, 7, 
and 14.  *Statistically different from all the groups (p < 0.05). n=8. 
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Figure 6.8 Hematoxylin & Eosin stained wound sections at day 14 for control, FGF-2, 
and syndesomes with FGF-2 treated groups. Quantification of granulation 
tissue area (mm2) in the wound sections. Size bar is 1mm. *Statistically 
different from all other groups (p < 0.05). n=8. 
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Figure 6.9 Images of the wound micro-sections immunostained with the cytokeratin 
antibody staining for epidermal layer containing keratin. Quantification of 
the epidermal regrowth beyond the fat defect in the skin. Size bar is 125μm. 
*Statistically different from all other groups (p < 0.05). n=8. 
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Figure 6.10 Movat’s pentachrome stained images of the wound tissue sections at day 14. 
Size bar is 1mm.  
 
6.3.2 Syndesomes Increase Blood Flow into the Wound Through Revascularization 
We found that there was a significant increase of blood perfusion at day 7 in the 
syndesomes with FGF-2 compared with other groups (Figure 6.11). By day 14, we had 
difficult imaging through the healed wound surface since the wound was almost healed 
for the syndesome group but not for the control group. The control wound showed 
maximum blood perfusion at day 14 compared to all other groups because it was the least 
healed among all the groups. Hence we only show results up to day 7 here. We suspected 
that it was because of new vessels forming in the wound like we saw in the hind limb 
ischemia experiment. Histological immunostaining for blood vessels (vWF) showed 
increased numbers of vessels in the wound bed (Figure 6.12). The granulation tissue 
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around the wound was more in FGF-2 group compared with all other groups, but was 
normal in the syndesome groups. We probed deeper into the immunological cascade 
related to the wound healing response. 
 
 
Figure 6.11 Panel of laser speckle contrast images of all the wounds at days 0 and 7. The 
color bar on the right shows relative blood perfusion (upper). Quantification 
of relative blood flow in the wound compared with day 0 (lower). 
*Statistically different from FGF-2 group (p < 0.05). n=8. 
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Figure 6.12 Immunostained images of the wound micro-sections stained for the 
endothelial cell marker von Willebrand factor. Quantification of the number 
of vessels in the wound bed in the immunostained images. Size bar is 
250μm. Inset is 3X magnified. *Statistically different from all other groups 
(p < 0.05). n=8. 
6.3.3 Syndesomes Modulate Immune Response to Pro-Wound Healing Phenotype 
Wound healing is a complex physiological process that has many players 
involved in it, especially the immune cells like macrophages [129]. The notion of distinct 
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macrophage phenotypes has been changing in the recent years and now macrophage 
characters are believed to be particularly plastic [114]. The wound tissue was biopsied, 
fixed and embedded in paraffin for micron thick sections. Immunostaining for M1 
macrophage marker (CD86) demonstrated significantly reduced expression for M1 
markers in the syndesome with FGF-2 (S4PL+FGF-2) and the syndesome alone groups, 
compared with FGF-2 alone (Figure 6.13). Thus, syndecan-4 protein is likely modulating 
the inflammatory response. The quantification was performed by calculating the ratio of 
the number of DAB positive cells to the total number of cells represented by their blue 
nucleus. Staining for the M2 macrophage marker (CD163) revealed significant up-
regulation of M2 phenotype in both S4PL and S4PL+FGF-2 groups compared to FGF-2 
alone (Figure 6.14). If we superimpose the CD86 and CD163 images on each other, we 
observe the distinct differences in all the treatment groups. To understand the temporal 
changes in the immune response to the therapy, we performed flow cytometry on the 
wound cells at days 2 and 6. The events were gated to have cells and then gated to sort 
out the macrophages (Figure 6.15). We noticed that there was a significant reduction 
from day 2 to 6, in the number of macrophage cells when treated with the syndesomes 
and FGF-2. The CD86 intensity remained constant for all the groups while the CD206 
intensity was higher in the syndesome with FGF-2 group, which means increase in the 
wound healing phenotype by day 6 (Figure 6.16). In conclusion, the syndesome therapy 
is driving the macrophages from the inflammatory to the wound healing phenotype, 
which is probably one of the reasons why we see enhanced wound healing in this 
treatment group. 
 
 
 
 
93 
  
 
 
Figure 6.13 M1 macrophage marker (CD86) immunostained images of the wound 
sections at day 14 (upper). Quantification of the ratio of the positively 
stained cells with the nuclear area (lower). Size bar is 500μm. Inset is 3X 
magnified. *Statistically different from FGF-2 group (p < 0.05). n=8. 
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Figure 6.14 Wound micro-sections immunostained with CD163 antibody which is a 
marker for alternatively activated M2 macrophages at day 14 (upper). 
Quantification of the ratio of the positively stained cells with the nuclear 
area (lower). Size bar is 500μm. Inset is 3X magnified. *Statistically 
different from FGF-2 group (p < 0.05). n=8. 
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Figure 6.15 Flow cytometry on wound cells.  (A) Primary gate named “Cells” on the 
entire population of wound cells by looking at the side scatter (SSC) versus 
forward scatter (FSC) plot. (B) Plot of side scatter (SSC) versus the 
fluorescent intensity of F4/80 in the gated populations of stained skin, 
unstained skin and FGF-2 treated wound. The secondary gate named 
“Macrophages” was defined such that the unstained skin doesn't have events 
and the stained skin has less than 10% cells inside the gated population. The 
fluorescent intensities of all the markers were evaluated for this secondary 
gated population in the next figure. 
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Figure 6.16 Plots of % cells and median fluorescent intensities. Black bars represent day 
2 and white bars represent day 6. (A) Graph shows % cells that are 
macrophages. (B) Graph shows median fluorescent intensity of PerCP CD86 
of all the groups. (C) CD206 median fluorescent intensity of the treatment 
groups. 
6.4 DISCUSSION 
This study is a major step in understanding how clinically common diseases, such 
as diabetes, metabolic syndrome and hyperlipidemia alter the response to growth factor 
therapy and in developing new therapeutic options effective in inducing neo-
vascularization of ischemic tissues in disease states. However, we acknowledge that there 
is a need to optimize the therapy targeting all the major growth factors. 
Previous studies support a role for syndecan-4 in wound healing and have found 
that syndecan-4 gene expression promotes fibroblast migration and regulates integrin 
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signaling and small GTPases during wound healing [77, 86]. Syndecan-4 also enhances 
keratinocyte migration [81] and is necessary for migration of fibroblasts in 3D gels [87]. 
In addition, syndecan-4 is induced in the skin following wounding in both mice and 
neonatal humans [88]. Finally, mice with knockout of syndecan-4 have delayed wound 
healing and angiogenesis [75]. Our previous studies have shown that syndesomes 
improve the signaling response to FGF-2, particularly the proliferation, migration and 
nuclear localization of FGF-2 in endothelial cells [67]. In addition, we found that 
syndesomes improved the angiogenic response to FGF-2 in diabetic mice in a 
subcutaneous implantation model [89].  
Here we have taken our previous studies a step further towards clinical 
translation. We have shown that the syndesome therapy is effective in healing full 
thickness wounds that are splinted to simulate the human healing behavior. Briefly, 
syndesomes enhance wound closure significantly more than any other treatment group by 
day 14. Although we have limited insight about the temporal progression of the healing 
process, it seems that the majority of the wound heals between days 7 and 14. Histology 
and immunostaining with cytokeratin confirmed that syndesomes up-regulate the re-
epithelialization beyond the initial wound margin. Like we observed in the last chapter, 
syndesomes improve the revascularization in the wound compared to other treatment 
groups. Since blood perfusion to the wound is imperative for healing [130-132], we think 
that syndesome-mediated angiogenesis assists in the wound healing process as well. 
Finally, and most notably, we observed immune modulation of macrophages from a pro-
inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, by the syndesomes, 
which was absent in the other treatment groups. This finding is phenomenal because 
inflammation is always accompanied with growth factor treatments [133, 134]. 
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Therefore, we envisage that this technology of co-delivering the co-receptors along with 
growth factors might be an effective solution to increasing the efficacy of growth factor 
therapy in a clinical setting. 
 
6.5 CONCLUSIONS 
The convincing results in ischemic tissue described in the last chapter spurred us 
to try the therapy in a wound healing experiment. Briefly, in this chapter we have shown 
the effectiveness of the syndesome therapeutics in a clinically relevant diseased ob/ob 
mouse model and an excisional-splinted wound model, which simulates the human 
wound healing process. Syndesomes enhanced cutaneous wound closure and re-
epithelialization in comparison with all the other groups. They also significantly 
increased the number of vessels in the wound bed aiding in the wound healing process. 
Remarkably, syndesomes caused immune modulation of macrophages towards an anti-
inflammatory phenotype without any adverse immune response. Thus, we are hopeful 
that this novel co-delivery system will be helpful to treat patients with wounds with 
underlying ischemic conditions.  
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Chapter 7: Conclusions and Future Work 
 
7.1  CONCLUSIONS 
The broad goal of this thesis was to understand the reasons behind the failure of 
clinical trials with growth factor therapy. We hypothesized that the reason for this 
therapeutic failure must lie in the target tissue characteristics. In animal models, ischemia 
is typically induced in a healthy animal by surgically ligating an artery either in the 
peripheral muscle or coronary artery; and wounds are fashioned on healthy animals, 
mostly without splints allowing them to shrink by contraction, which is absent in humans. 
Consequently, the wound or ischemia develops acutely in an animal that is otherwise 
healthy. In human clinical use, the patient has developed ischemia or chronic wounds 
most often through a long-term disease process. Thus, by the time patients have 
developed clinical recognizable symptoms, they have had the disease for an extended 
period of time and the considerable compensatory mechanisms of the human body have 
been overwhelmed. These compensatory mechanisms could include the induction of the 
very angiogenic factors that we are attempting to use as therapeutic inducers of blood 
vessel growth. Accordingly, the presence of long-term disease likely implies the presence 
of innate mechanisms to defeat growth factor therapy without modification.  
This thesis describes a novel and innovative line of investigation to enhance the 
growth factor-based treatment of the disease. Rather than focusing on exploring new 
growth factors, cell types, or combinations of these, we proposed a two-pronged 
approach to the problem: (1) identify the “broken links” in the known growth factor 
pathways in clinical patient samples and animal models of disease (2) co-treat diseased 
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tissues with novel therapeutics that repair revascularization signaling pathways to allow 
growth factor therapies to be efficacious in diseased condition. 
This work, to the best of our knowledge, is the first in-depth functional analysis of 
why diseased tissues are resistant to growth factor signaling and how the functional 
ability to a healthy state can be restored under these conditions. Throughout the study, we 
have used the ob/ob mouse model, which is a leptin-deficient mouse with clinically 
relevant characteristics including obesity, hypercholesterolemia, pre-diabetes, hyper-
glycemia, and insulin resistance. To the best of our understanding, this is the best model 
to simulate the diseased condition in human patients with diabetes and other vascular 
complications. Our studies show significant loss of the co-receptors due to presence of 
disease in the ob/ob mouse model compared to healthy mice, leading to immense 
resistance to growth factor-based angiogenesis (Chapter 3). We decided to focus on one 
of the most important growth factors, FGF-2 and studied one out of the two co-receptors 
(sdc-1 and sdc-4). Co-delivery of the missing co-receptor protein with the growth factor 
was able to overcome some of the resistance (Chapter 4). To match the response of the 
normal healthy mouse, we might have to deliver all the missing co-receptors with the 
associated growth factors. However, this was a first proof-of-concept experiment that 
confirmed our hypothesis. To test the effectiveness of the therapy in a pertinent model, 
we decided to use hind limb ischemia and an excisional wound model with diseased 
ob/ob mice. The syndesomes not only enhanced revascularization in the ischemic limbs 
(Chapter 5) but also improved the wound closure and re-epithelialization of wounds 
(Chapter 6) while showing minimal adverse inflammatory response.  
On a global level, the basic findings and techniques developed in this thesis 
represent a paradigm shift in how growth factor signaling pathways are approached from 
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a therapeutic perspective. While this work focuses on ischemia and vascular disease, 
growth factors are intimately involved in the mechanisms of many diseases including 
cancer growth and metastasis, wound healing, and the immune response to infection. 
Thus, the innovative techniques we will develop will have a broad impact on the 
understanding and treatment of diverse disease states.  
 
7.2 FUTURE WORK 
7.2.1 Large Animal Studies 
With the conclusive results that we have described in this thesis in the mouse 
model, we would like to test our therapy in a large animal model so that we can quickly 
translate into the clinic. We have forged collaboration with Bridge PTS (Preclinical 
Testing Services) in San Antonio and we will be starting the studies on a porcine model 
soon. Various porcine models of both type-1 and type-2 diabetes have been reported in 
the literature [135]. The most widely used model uses Yucatan minipigs with multiple 
low dosage injections of streptozotocin or alloxan to induce diabetes before the start of 
the study, and simultaneously feeding the animal with a high fat diet to induce metabolic 
syndrome [135, 136]. We will have an n=5 and will continue the study up to 4 weeks to 
assess the temporal response to the treatment groups. The wound closure rate will be 
evaluated using the macroscopic dimensions of the wound over the course of the study. 
Revascularization will be monitored with the laser speckle contrast imager that shows 
relative blood perfusion and hyper spectral spatial frequency domain imager to observe 
the tissue oxygenation and health.  
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7.2.2 Intra-cellular Trafficking Studies 
We would also like to investigate the subcellular mechanism of syndesome uptake 
and action. FGF-2 will be tagged with Alexa Fluor 647 succinimidyl ester for 1 hour at 
room temperature as previously shown in the lab [67]. The HEK293Ta cells will be 
transfected with fluorescent Rab5 [137], Rab7 [137], and Rab11 [138] proteins. The five 
different compositions of syndesomes will be delivered to endothelial cells in vitro and 
tracked over a period of two days using a confocal microscope. We will also use adult 
human dermal fibroblasts from healthy and diabetic sources to tease out differences in 
subcellular trafficking. This will give us insight into how the syndesomes alter growth 
factor trafficking at the subcellular level and locations of various cytosolic components 
during the response to growth factor therapy.  
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